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ABSTRACT
Neonatal Abstinence Syndrome in West Virginia: Trends, risks, and effectiveness of in
utero exposure detection
Meagan Stabler
This dissertation examined neonatal abstinence syndrome (NAS) in West Virginia (WV).
Specifically, three studies were conducted that investigated state and regional trends, risks
related to NAS, and effectiveness of in utero exposure detection. The first study described
regional incidence rates, trends of antenatal drug class-specific exposures, and NAS diagnoses in
WV between 2007 and 2013. The findings indicated a 4-fold increase in WV statewide incidence
rates of NAS during this time period, which was three times the national annual average. The
second study identified the risk of NAS, risk of NAS requiring pharmacologic treatment, and
odds of NAS controlling for potential confounders among substance-using pregnant women who
gave birth at Ruby Memorial Hospital between January 1st 2009 and March 3rd 2014. Results
indicated that multiple substances could lead to a NAS diagnosis and that variations existed
between drug class-specific exposure and heightened risk of NAS and NAS requiring
pharmacological treatment. The third study assessed the effectiveness of maternal urine drug
screens, maternal substance use ICD-9-CM diagnostic codes, and neonatal ICD-9-CM exposure
codes in detecting antenatal substance use among a subpopulation from the second study. These
alternative methods performed poorly, with low sensitivity values, when compared to a
meconium analysis (i.e., a neonatal non-invasive biological drug screen). Therefore, solely
utilizing alternative screening methods taken at labor and delivery would likely underestimate
the number of exposed newborns. This is important because unidentified newborns could be
released from the hospital prior to their withdrawal symptom onset and/or left medically
untreated. Taken together, these findings provide both research and clinically relevant
implications regarding trends of NAS in WV, drug class-specific risk of NAS and NAS requiring
pharmacological treatment, and the effectiveness of in utero exposure detection.
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Chapter 1
Overview of the Research
1.1 Substance Use in Pregnancy
Substance use during pregnancy is a growing phenomenon associated with negative
health outcomes for mothers, as well as newborns. In 2012-2013 the national annual average of
self-reported illicit drug, alcohol, and tobacco use among pregnant women aged 15 to 44 years
was 5.4%, 9.4%, and 15.4%, respectively.[1] Rates of illicit drugs, alcohol, and tobacco use
decreased with older maternal age and were lower among pregnant women in their third
trimester compared to women in their first and second trimesters.
Although national rates decreased with maternal age and trimester during pregnancy, the
rate of reported illicit drug use among pregnant women aged 15 to 44 years increased from 4.4%
in 2010 to 5.4% in the 2012-2013 annual average.[2] The rise in national trends of antenatal
illicit drug use is also illuminated by the increased proportion of pregnant women admitted for
substance abuse treatment for drug abuse only (i.e., not alcohol). Specifically, treatment
admissions for drug abuse increased from 51.1% in 2000 to 63.8% in 2010.[3]
In the state of West Virginia (WV), drug screening estimates have revealed that 19.2%,
or one in five, newborns are exposed to licit and/or illicit drugs in utero.[4] Although surprising,
this statistic is in line with the state’s drug epidemic. In 2012, WV had the highest age-adjusted
death rate for drug poisonings and the third highest prescribing rate of opioid analgesics in the
country.[5] The state’s high neonatal exposure, drug overdose, and prescribing rates indicate that
the drug epidemic has influenced one of the most vulnerable populations, pregnant women and
their unborn children.
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Nearly all noxious substances used during pregnancy can induce drug-related adverse
events. Largely, obstetric and neonatal health outcomes of in utero substance exposure include
miscarriage, developmental defects, premature birth, and behavioral and cognitive
complications.[6] Drugs consumed by the mother can readily transfer across the placenta to the
fetus. The extent of placenta transfer varies base on the substances molecular weight, the pH
when the drug is 50% ionized, and the drug’s ability to bind to the plasma protein.[7] The
influence of dosage effects is controversial, as it is not always true that higher doses of a noxious
substance is more deleterious than lower doses. Dosage effects on the embryo/fetus depend on
when exposure occurred during the developmental stage, the dose level and pattern of sequential
administration, as well as the route of administration.[8] Other variables that influence defects in
the fetus after in utero substance exposure include the stage of embryonic development, genotype
of the mother and fetus, drug interactions, and other obstetric factors.[8]
There are three stages of susceptibility associated with embryonic development. In the
first stage, or embryogenesis, the drug can be lethal, but surviving embryos are not likely to
develop associated malformations (first two weeks of pregnancy).[9] The second stage of
organogenesis or organ differentiation is when the embryo is most susceptible to fetal
malformations (3 to 8 weeks of pregnancy).[8] In addition, the spectrum of anomalies can be
determined from the specific timing of exposure, as teratogens affect organ systems at organspecific stage of development. The third stage of embryonic development, called organ growth,
is where noxious influences can impact fetal growth but does not directly alter organogenesis (8
to 10 weeks of pregnancy).[8] After embryogenesis, the brain, gonadal tissues, and lungs
continue to develop in the second and third trimester and therefore in utero exposure to noxious
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substances at that time can negatively impact the fetus.[10] Use of substances throughout the
entire pregnancy can also result in neonatal withdrawal.[11]
1.2 Neonatal Abstinence Syndrome
An increase in antepartum drug use is also made evident by vast increase in neonatal
abstinence syndrome (NAS). NAS is a constellation of central nervous system, metabolic
vasomotor, respiratory, and gastrointestinal disturbances a neonate experiences resulting from
drug withdrawal following delivery [11, 12]. NAS most commonly results from in utero
substance exposure, but postnatal NAS from discontinuation of analgesic medications in the
newborn, or iatrogenic NAS, can also result in a diagnosis.[13, 14] Associated symptoms of
NAS include high-pitched crying, jitteriness, convulsions, tremors, sweating, fever, mottling,
excessive sucking or rooting and therefore poor feedings, vomiting, and diarrhea. Severe cases
can result in seizures and, although rare, withdrawal can indirectly result in neonatal death.[15]
Despite the associated health ramifications of NAS, the incidence has greatly increased,
which has strained fiscal and hospital management resources. Between 2000 and 2012 the
national incidence of NAS increased nearly 500% from 1.2 to 5.8 per 1000 hospital births per
year.[16, 17] This sharp increase is most likely due to the prescription opioid epidemic.[17, 18]
Opioid pain reliever prescriptions grew 4-fold in the last decade, which was paralleled by an
increase in opioid-related overdose deaths.[19] The prescription opioid epidemic has infiltrated
America’s pregnant population, as 1 in 5 pregnant women filled an opioid prescription between
2000 and 2007.[20, 21]
In addition, estimates adjusted for inflation, approximate that the average medical cost of
delivering a NAS baby increased from $39,400 in 2000 to $53,400 in 2009, of which 77.6% of
costs were charged to respective state Medicaid programs.[17] The total US public health and
3

medical cost resulting from babies born with drug withdrawal in 2009 was between 70.6 and
112.6 million dollars.[18] In addition, neonatal intensive care units are often ill-equipped to
handle the influx of neonates born with drug withdrawal. An average of one baby is born per
hour with drug withdrawal in the United States and the mean length of hospital stay for these
newborns is 16 days, compared to non-NAS diagnosed infant of 3 days.[17]
Neonatal withdrawal most commonly results from in utero opioid exposure, although
other drug exposures have been linked to NAS diagnoses.[17, 22] Alcohol [23-25], nicotine [2629], cocaine [30-32], phencyclidine (or PCP) [33], methamphetamine [34], benzodiazepine [35,
36], and other psychotropic medication [37-40] antenatal exposures produce similar withdrawallike signs and symptoms and thus neonates with these exposures have been diagnosed with NAS.
Among neonates with antenatal opioid exposure, 55% to 94% develop withdrawal symptoms and
are then closely observed for diagnosis and/or treatment.[11]
In 2014, WV (the state in which the studies were conducted) held a statewide meeting
where neonatologists, insurance, hospital, perinatal partnership, and WV Department of Health
and Human Resource officials reached consensus on a standardized definition and diagnostic
criteria for NAS. Representatives agreed that NAS includes withdrawal from opioid and nonopioid substances and the definition is not limited to cases that require pharmacological
treatment. Rather, cases are defined on a known in utero exposure and clinical signs and
symptoms of withdrawal. Neonates considered high-risk for NAS are those who exhibit
withdrawal symptoms, have a positive neonatal drug screen, or are born to mothers identified
with a substance use disorder, who exhibit signs of drug use, lack prenatal records/visits, or have
a positive urine drug screen. Additional clinical conditions that indicate high-risk neonates
include intrauterine growth retardation, preterm delivery, abruptio placentae, or cardiovascular
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accidents in the mother or infant. High-risk neonates require stringent pediatric observation,
toxicology testing, and immediate NAS scoring to determine severity and treatment.
At the study hospital, NAS severity and treatment protocols were assessed via the
Modified Finnegan Scoring system (see Appendix A).[41] All high-risk neonates were
evaluated prior to feeding, every 2 to 4 hours after birth. The total Finnegan score (46 max) is the
sum of 21 individual scores calculated by presence and severity of symptoms associated with in
utero opioid exposure. NAS was diagnosed when an infant scores ≥8 during two consecutive
screenings. Non-pharmacologic treatment occurred at the onset of diagnosis, which included
kangaroo care, swaddling, high caloric diet, and a low-stimuli environment. Pharmacological
treatment was necessary when NAS scores were more severe (i.e., infants with a score of ≥12 or
greater on three consecutive occasions or a combined score of ≥28). The standard treatment was
oral morphine solution with an optional adjunctive treatment of phenobarbital. Dosage regiments
throughout the process of initiation to cessation of treatment can be referred to in appendix B.
The primary goal was to cease NAS treatment and reach infant rhythmic feeding, sleeping, and
weight gain with the least amount of medication.
1.3 Toxicology Screening
Detection of maternal substance use during pregnancy is necessary, in order to initiate
substance abuse treatment and allocate education and support resources for the soon to be
mother. For example, methadone or buprenorphine opioid maintenance therapy (OMT) is the
standard of care for women with opioid use disorders during pregnancy.[12] Although OMT
often results in NAS, overriding benefits for the mother-infant dyad include stabilization on the
drug to avoid illicit opioid use and fetal in utero withdrawal during pregnancy, encouraged
prenatal care and participation in other educational interventions, and reduced associated
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criminal and risk-based activities.[12] In addition, NAS is an expected and treatable condition
among neonates born to women enrolled in OMT.
Identification of antenatal substance use is also beneficial to health care providers
because it enables them to better prepare for potential obstetric and neonatal clinical implications
at birth, and at-risk neonates would be identified for immediate NAS observation, treatment, and
extend hospital length of stay.[12] Extending neonatal hospital length of stay is important
because, depending on various drug exposures, environmental and genetic factors, withdrawal
often occurs 48 to 72 hours after delivery. A neonate could be mistaken as healthy and
discharged home prior to the start of withdrawal symptoms.[42]
Toxicology testing is indicated in high-risk mothers and neonates, as described in section
1.2. Maternal urine drug screens (UDS) during pregnancy is a traditional method of toxicology
testing. UDS is encouraged to take place at the first and sequential prenatal care visits throughout
pregnancy. The drug screen can still miss women who are positive for antenatal substance use
with this level of screening [43, 44], therefore in 2011 the study hospital adopted a policy of
universal maternal UDS screen at labor and delivery hospital admission. This type of screening
can feasibly be conducted in mass quantities at delivering hospitals with a quick turnaround time
to provide clinician indications of antenatal substance use.[45] Limitations of UDS include the
short window of detection (i.e., metabolites may detect a few days to a few weeks with maternal
UDS, neonatal UDS can only detect maternal antenatal use a few day prior to delivery) and there
are challenges with collecting neonatal urine because the collection bag regularly irritates the
infants’ skin, often failing to adhere.[45]
Meconium is the specimen of choice for detecting neonatal in utero exposure. It is
advantageous because of the associated long window of detection (i.e., 12th to 16th week of
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gestation onward).[45] Meconium testing is also feasible with costs per unit similar to that of
neonatal UDS.[46, 47] Unfortunately, receipt of meconium test results can take up to three days
due to specimen delay, confirmation of positives are necessary due to the potential for falsepositive results, and specimen samples can be compromised and/or unavailable.[48]
Umbilical cord tissue (UCT) drug screens are comparable to meconium in that they have
the same long window of detection and they have high agreement (greater than 90%) on
amphetamines, opioids, cocaine, cannabinoids, and phencyclidine in utero exposure
detection.[49, 50] An additional benefit of UCT drug screens are their fast turnaround testing
time and the ability to collect an uncompromised specimen sample on every neonate.[48] UCT is
considered a new alternative method of measuring in utero exposure, thus less is known about
disposition of drugs in the specimen, which makes it more difficult to interpret results.[45] In
March 2013, the study hospital enrolled in a quality improve protect and changed their neonatal
biological drug screening protocol from meconium specimens of at-risk neonates to universal
UCT screening. This change was largely due to the perceived benefit of universal screening[4]
and the ability of UCT to specifically detect buprenorphine, which was previously undetectable
in meconium.
1.4 Gaps in the Literature
Due to the rise in opioid (prescription and illicit) drug misuse and NAS, this area of
research has gained national attention. There is evidence-based treatment for pregnant women
with opioid use disorders, which includes methods for maternal screening, OMT initiation, and
maternal cross-disciplinary care.[12, 51, 52] Standards of care also exist for evaluation,
assessment, and treatment of infants diagnosed with NAS, though guidelines are tailored to an
opioid in utero exposure.[53, 54]
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Generally, NAS is defined in the context of mothers with opioid use disorders and/or
mothers who are treated via buprenorphine or methadone OMT during pregnancy. Therefore,
NAS among neonates with non-opioid in utero exposures are not typically captured in the
literature.[55] To date, few studies have compared NAS severity across maternal drug using (i.e.,
groups of opioid and opioids with other substances).[56-61] Only one other study assessed risk
of NAS requiring treatment among opioid and non-opioid exposed groups, though the study
population consisted solely of neonates who were diagnosed with NAS.[62] Assessment of
maternal poly-substance use with opiates or by multiple drug groups and neonatal outcomes,
other than NAS, have also been measured.[63-67]
NAS rates are typically reported in the literature via hospital, state, or national settings.
West Virginia state and sub-state NAS rates and trends of NAS are not currently documented. If
the distribution of NAS diagnoses were indicated by patient’s residence, then prevention efforts
and health care services could more appropriately allocate resource to populations that could
benefit most.
To the authors’ knowledge, four studies have compared the effectiveness of in utero
substance exposure detection among alternative screening methods.[42, 46, 68, 69] Of these
studies, three assessed meconium drug screening and two utilized meconium and screened for
cocaine and opiates exposure. The current study is the first to compare the effectiveness of
alternative screening methods at labor and delivery admission and to determine diagnostic
effectiveness of maternal substance use (International Classification of Diseases, 9th Revision,
Clinical Modification) ICD-9-CM codes and neonatal ICD-9-CM exposure codes compared to
meconium results.
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1.5 Specific Aims
The overarching goal of this dissertation and future research is to better understand the
risk and trend of NAS, as well as the effectiveness of in utero substance exposure detection
methods. Knowledge generated will help guide public health interventions, the allocation of
resources, and accurate identification of exposed neonates to ensure proper observation and
treatment. Specifically, this dissertation is composed of three separate but related studies that
aims to:


Chapter 2: Describe regional incidence rates and trends of neonatal drug class-specific in
utero exposure and NAS diagnoses WV between 2007 and 2013.



Chapter 3: Identify the risk of NAS, risk of NAS requiring pharmacological treatment,
and odds of NAS controlling for potential confounders among substance-using pregnant
women who gave birth at Ruby Memorial Hospital between January 1, 2009 and March
3, 2014.



Chapter 4: Assess the effectiveness of maternal urine drug screens, maternal substance
use ICD-9-CM diagnostic codes, and neonatal ICD-9-CM exposure codes in detecting
antenatal substance use among substance-using pregnant women who gave birth at Ruby
Memorial Hospital between January 1, 2009 and March 3, 2014.
Chapter 3 utilized the biopsychosocial model as a theoretical framework, in which to

structure the selection of potential risk factors for NAS (see Figure 3.1). The biopsychosocial
model assesses health-related outcomes via a holistic multi-faceted approach. Biologic,
psychological, and socioeconomic factors of the mother-infant dyad associated with NAS and
specific maternal substance use were identified.[70] In order to calculate the least-biased
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estimate of the effect of in utero drug class-specific exposure on the odds of NAS, confounding
was explored via the identified factors and controlled in the analysis.
1.6 Overview of Methodologic Approach
The first study (chapter 2) utilized the WV Health Care Authority, Uniform Billing
Database for years 2007 to 2013. This data was linked by region of patient residence, in order to
calculate regional rates and trends. Data collection for this study started in 2007 because single
diagnostic reports from the HCA prior to that date were unreliable. The HCA data exclusion
criteria were HIV discharges, admission type not equal to 4 (newborn), residency in state other
than WV, and any diagnostic code equal to ICD-9-CM code 779.9 (stillborn). HIPAA
compliance measures did not allow the HCA to disseminate information on newborns diagnosed
with HIV. Multiple birth pregnancies are counted as separate live births. The outcome was
defined as a primary or secondary NAS diagnosis, via ICD-9-CM code 779.5, labeled drug
withdrawal syndrome in newborn. HCA de-identified data was available upon request, once a
limited data agreement that ensured HIPAA privacy standards were met. Data could only be
released if the minimum cell size was 30 or greater. Due to the relatively small occurrence of
NAS cases among the 55 counties in WV each year, the data was aggregated by regions. The six
geographic sub-state regions were defined from the Substance Abuse and Mental Health Services
Administration (SAMHSA) and reported in 2008-2010 National Survey of Drug Use and Health
(NSDUH) report. This report found different variations of mental health and substance use
problems among the six sub-state regions in WV.[71]
The second and third studies conducted a retrospective medical chart review of
substance-using pregnant women who gave birth between January 1st 2009 and March 3rd 2014
at Ruby Memorial Hospital in Morgantown, WV. Electronic medical records via the hospital’s
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EPIC (i.e., WVU’s electronic medical record system) were reviewed to determine previous
maternal drug exposures and subsequent maternal and neonatal outcomes. A WV University
Hospital decision support analyst generated a mother-infant dyad study sample in accordance to
the studies eligibility criteria, which contained patients’ medical record number (MRN) and other
study variables that were readily available. Four additional codes then manually extracted
additional retrospective data via the patients MRN identifier in EPIC and entered/stored the data
in REDCap (Research Electronic Data Capture), which is a HIPAA compliant and protected data
collection tool (see appendix C and D). In order to maintain confidentiality of data and privacy
of subjects, arbitrary study IDs were randomly assigned to each mother-infant dyad and one
master list was created that linked original participant MRNs to study IDs. This master list is
permanently kept in a secure and protected file within REDCap.
Descriptive summaries and prevalence estimates were assessed using frequencies,
proportions, means, and standard deviations, as well as non-parametric equivalents for nonnormal data. Differences in proportions of NAS diagnosis and NAS requiring treatment among
maternal and neonatal characteristics were examined using the Pearson Chi-square and Student’s
t-test. When appropriate, the non-parametric and exact equivalent tests were conducted.
The first study visually demonstrated NAS incidence rates via annual comparative WV
region maps utilizing ArcGIS 10.2 software. In addition, the Mantel-Haenszel Chi-square (χ2MH)
test was used to test for associated when NAS incidence rates were stratified by both region and
hospital and the Cochran-Armitage test (Z) for trend was utilized to test for linear trends in the
proportion of NAS diagnosis from 2007 to 2013.[72]
In the second study potential confounders were identified via the change-in-estimate
method; if the effect estimate change was 10% or more, the covariate was included in the logistic
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regression model.[73] The third study compared the performance of alternative drug screening
methods to meconium test results via sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy measures. Binomial proportion estimates and asymptotic standard
error (ASE) 95% confidence intervals were reported. Data management and analyses were
conducted using SAS 9.4 (SAS Institute Inc., Cary, North Carolina) and significance was defined
with a 2-tailed alpha of .05.
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Chapter 2
Neonatal Abstinence Syndrome in West Virginia Sub-State Regions, 2007-2013
Abstract
Objective: The opioid epidemic is a public health threat with consequences affecting newborns.
Neonatal Abstinence Syndrome (NAS) is a constellation of withdrawal symptoms resulting
primarily from in utero opioid exposure. Nationwide estimates show a sharp increase in NAS;
however, minimal research has assessed NAS and neonatal exposure in WV. Method: The 20072013 WV Health Care Authority, Uniform Billing Data were analyzed for 119,605 newborn
admissions with 1,974 NAS diagnoses. NAS (ICD-9-CM 779.5), expressed as incidence rate (IR)
per 1,000 live births, and exposure diagnostic codes (opioids (760.72), hallucinogens (760.73),
and cocaine (760.75)) were utilized. Results: Between 2007 and 2013, NAS IR significantly
increased from 7.74 to 31.56 per 1,000 live births per year (Z: -19.10, P < .0001). During this
time period, opioid exposure increased (Z: -9.56, P < .0001), while cocaine exposure decreased
(Z: 3.62, P = .0003). In 2013, the southeastern region of the state had the highest NAS IR of
48.76 per 1,000 live births. NAS infants were more likely to experience other clinical conditions,
longer hospital length of stay, and be insured by Medicaid. Conclusion: Statewide NAS IR and
exposure has greatly increased since 2007. This alarming trend is deleterious for the health of
WV mother-child dyads and it strains the state’s healthcare system. Therefore, WV has a unique
need for prenatal public health drug treatment and prevention resources, specifically targeting the
rural southeastern region. Further examination of maternal drug-specific use trends and general
underutilization of neonatal exposure ICD-9-CM codes is indicated.
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2.1 Introduction
With the increase in opioid prescribing and prescription overdose deaths, it is evident that
an opioid epidemic has emerged in the United States (US).[74] This epidemic has far reaching
consequences that has affected one of the most vulnerable populations, pregnant women and
infants. Neonatal abstinence syndrome (NAS) is a constellation of signs and symptoms of
withdrawal that occur in newborns, as a result of illegal or prescription in utero drug
exposure.[12] NAS-like symptoms are characterized as central nervous system, gastrointestinal,
respiratory, and autonomic disturbances.[11, 12] Specific signs and symptoms include:
irritability, feeding difficulties, excessive sucking and/or crying, hyperactive reflexes, sleep
problems, vomiting, diarrhea, and sometimes seizures. NAS most commonly results from
antepartum opiate use, but the diagnosis has occurred in the context of other illicit and
prescription drugs.[22] The syndrome is diagnosed in 55% to 94% of newborns exposed to
opioids in utero and it is commonly a comorbid diagnosis with other conditions such as low
birthweight, preterm birth, and intrauterine growth retardation.[11] In addition, the average
medical cost of delivering a NAS infant reached $1.5 billion in 2012, with 81% of costs charged
to respective state Medicaid programs.[16]
From 2000 to 2009 and 2000 to 2012, maternal opiate use during pregnancy increased
from 1.19 to 5.63 per 1,000 hospital births, and the incidence of NAS in the US increased nearly
500% from 1.2 to 5.8 per 1,000 hospital births per year, respectively.[16, 17] In 2012,
nationwide geographic variations in NAS showed that the largest rates occurred in the East South
Central parts of the country (Kentucky, Tennessee, Mississippi, and Alabama) with 16.2 per
1,000 live births.[16] Minimal research has addressed NAS and neonatal in utero substance
exposure in rural settings, as granularity of the geographic variation in NAS study findings do
not include WV specific rural state or sub-state rates.
14

Although substance use in pregnancy is a concern nationwide, the state of WV faces
distinct challenges due to issues related to rurality, poverty [75], drug use, and other factors
influencing poor infant health outcomes. WV is ranked as the third most rural state, with a
population of 950,184 residing in 2010 Census Bureau defined rural areas.[76] In addition, it is
the only state completely immersed within the Appalachian region.[77] The top 5 ranked states
for age-adjusted drug overdose mortality rates (i.e., WV, Kentucky, New Mexico, Nevada, and
Utah) are designated as predominately rural states by the Office of Rural Health Policy.[78, 79]
Specifically, WV has the highest age-adjusted death rate from drug poisoning in the country
(36.3 per 100,000 population) and the third highest prescribing rate of opioid analgesics (137.6
per 100 people).[5] Substance use during pregnancy is more common among women residing in
rural areas compared to urban areas.[80-83] Rural pregnant women have increased rates of
prescription opiate, benzodiazepine, and injection drug use compared to pregnant women from
urban areas.[81] In addition to increased drug use, pregnant women with opioid use disorder are
faced with societal stigmas and lowered accessibility to substance abuse treatment in rural areas
where lack of resources and greater disparities exist.[84-87]
Infants born to women residing in rural areas are at an increased risk of presenting
adverse birth outcomes.[84] Compared to the rest of the US, WV statistics provide additional
evidence emblematic of poor infant health outcomes: higher teen (15-19 years of age) birth rates
(4.5%), higher prenatal smoking rates (26.3%), and higher cesarean section delivery rates
(36.5%).[88] In 2014, the state was ranked 11th nationally for infant mortality, 7th for percent of
low birthweight babies, and 13th for percent of preterm live births.[75] In terms of neonatal
substance exposure, a 2009 statewide study of cord tissue samples showed that 19.2% of infants
were antenatally exposed to licit/illicit drugs and alcohol, excluding nicotine.[4]
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With the increase in antepartum opiate use, NAS diagnosis, and hospital utilization, NAS
is a major public health concern. There is no WV statewide or regional estimate of the incidence
of NAS, thus the purpose of the current study is to outline the scope of the problem in the
primarily rural state of WV. The primary objectives were to examine state- and region-level
NAS and drug-specific trends between 2007 and 2013, as well as to present infant patient
characteristics associated with NAS and hospital-level NAS rates for WV birthing hospitals.
2.2 Methods
Data Source and Identification of Sample
A serial cross-sectional analysis was conducted with data from the WV Health Care
Authority (HCA), Uniform Billing Database (UB). The claims data were collected at the
conclusion of every year from 2007 to 2013. The HCA provided de-identified hospital inpatient
discharges of WV resident newborn admissions that were delivered in-state, excluding stillborn
(ICD-9-CM code 779.9) and HIV diagnoses. Multiple birth pregnancies were counted as separate
live births. The UB data reflects the final amount billed/charged on the newborn’s claim and not
the total cost of delivery. Therefore, an associated healthcare expenditure analysis was not
conducted.
Infants born in hospitals that delivered 10 newborns or less within the 7 year period were
excluded from the study (n=15). This helped eliminate bias, as these infants could have been
diagnosed and treated differently than those delivered at registered birthing centers. In addition,
newborns were excluded from the study (n=758) if they were diagnosed with any of the
following conditions: intraventricular hemorrhage (ICD-9-CM, 772.1x), periventricular
leukomalacia (ICD-9-CM, 779.7), necrotizing enterocolitis (ICD-9-CM, 777.5x), spontaneous
intestinal perforation (ICD-9-CM, 777.6), or bronchopulmonary dysplasia (ICD-9-CM, 770.7).
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These newborns were likely to have prolonged length of stay in the hospital and were more
likely to have received opiate medication resulting in iatrogenic NAS. Likely iatrogenic NAS
cases were excluded from the study because the etiology of withdrawal differs from antenatal
exposed NAS.[17] Total excluded cases equal less than 1% of the baseline population (i.e.,
0.99% of 120,378 observations).
Outcome
NAS incidence rate (IR) per 1,000 live births was the outcome of interest. NAS (yes, no)
was defined via the presence of an ICD-9-CM 779.5: ‘Drug withdrawal syndrome in newborn’
diagnosis (diagnostic fields 2-18). In order to comply with the federal Health Insurance
Portability and Accountability Act (HIPPA) privacy standards, the data were aggregated by 6
geographic sub-state regions pre-defined by the Substance Abuse and Mental Health Services
Administration (SAMHSA) 2008-2010 NSDUH report (see Figure 2.1). The SAMHSA report
outlined unequal distributions of mental health and substance use occurrence among the sub-state
regions.[71]
Neonatal substance exposure diagnosis (yes, no) was the secondary outcome. The ICD-9CM codes associated with noxious substances affecting infants and breastfeeding children
(760.7x) were captured to identify the type and magnitude of exposure. These diagnoses
represent exposure to narcotics, including heroin and prescription opioid analgesics (760.72),
hallucinogens (760.73), and cocaine (760.75).
Descriptive Variables
Descriptive patient-level characteristics associated with substance use and
obstetric/neonatal health outcomes were analyzed. These variables included the newborns’
gender, hospital length of stay, clinical conditions, in utero substance exposure, and mothers’
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insurance type. Seizures, adverse respiratory symptoms, and feeding difficulties are clinical
conditions associated with NAS diagnosis.[11, 12, 89] Diagnoses and respective ICD-9-CM
codes, seizures (779.0, 780.3), respiratory symptoms (769.x, 770.x), and feeding difficulties
(779.3), were coded to better describe the sample. Mothers’ insurance type was a 4 category
variable that encompassed Medicaid, Medicare, PEIA (WV Public Employees Insurance
Agency), and Other (e.g., commercial companies and self-payers). In addition to the outcome,
neonatal substance exposure codes (i.e., ICD-9-CM 760.72, 760.73, and 760.75) were described
within the presence of a NAS diagnosis. These exposures are presented as separate binary
variables (i.e., diagnosed versus not diagnosed), as newborns could have polysubstance
exposure.
Statistical Analysis
NAS IRs were calculated using the number of NAS diagnoses as the numerator and
respective number of live births in the denominator and multiplied by 1,000 to obtain IRs per
1,000 live births by region and year. This measure of infant morbidity captures newly occurring
NAS diagnoses, which exhibits short duration and occurs only once during infancy.[90]
Therefore, each newborn’s person time at risk was equal to 1 unit (i.e., the number of annual live
births).
The outcome was visually demonstrated via annual comparative WV region maps
utilizing ArcGIS 10.2.[91] NAS IRs were stratified, in order to be representative of the
SAMHSA 6 WV sub-state regions (see Figure 2.1).[71] Stratified by birthing hospitals, the
hospital-level NAS IRs were represented by the diameter of circles on the GIS regional map (see
Figure 2.2).
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To assess overall differences in proportions of newborns with and without NAS by year,
the Mantel-Haenszel Chi-square (χ2MH) test was stratified by both region and hospital.[72]
Additionally, the Cochran-Armitage test (Z) for trend was utilized to test for linear trends in the
proportion of NAS diagnosis from 2007 to 2013. Differences among delivery characteristics (i.e.,
neonatal length of stay, insurance type, and clinical diagnoses) and NAS diagnosis were tested
using the Pearson Chi-square (χ2) test for categorical characteristics and the Wilcoxon RankedSum test (z) for continuous characteristics. An a priori two-sided type 1 error of 5% was
considered statistically significant. Statistical analyses were conducted using SAS® 9.4 (SAS
Institute Inc., Cary, NC).
Ethics Statement
Approval of the current study was obtained from the Institutional Review Board of the
primary author’s academic institution (Protocol # 1405305752).
2.3 Results
NAS and Exposure
Overall, the current study analyzed 119,605 live births with 1,974 NAS diagnoses (i.e., a
total of 16.5 per 1,000 live births) (see Figure 2.2). With regards to rates over time, between
2007 and 2013 the statewide rate of newborns diagnosed with NAS significantly increased from
7.74 to 31.57 per 1,000 live births per year (Z: -19.10, P < .0001). There were statistically
significant differences in the magnitude of the trend in NAS IR by region; region 1 (Z: -4.73, P <
.0001), region 3 (Z: -2.41, P = .016), region 4 (Z: -10.51, P < .0001), region 5 (Z: -8.00, P <
.0001), and region 6 (Z: -18.77, P < .0001) significantly increased over time. In 2013, the
southeastern region of the state (i.e., region 5) had the highest NAS IR of 48.76 per 1,000 live
births. There was no significant trend of NAS diagnoses in region 2 (Z: -0.002, P = .999). After
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adjusting for regional variation, there was an overall significant increase in NAS diagnoses from
2007 to 2013 (χ2MH=429.78, 6 d.f., P < .0001).
Between 2007 and 2013, the statewide rate of newborns diagnosed with neonatal
substance exposure per 1,000 live births significantly increased from 1.89 to 8.09 for narcotics
(Z: -9.56, P < .0001) (see Figure 2.3). Region-specific narcotic exposed diagnoses significantly
increased over time in regions 1 (Z: -5.30, P < .0001), 2 (Z: -4.24, P < .0001), 3 (Z: -2.02, P =
.04), 4 (Z: -8.46, P < .0001), and 6 (Z: -2.52, P = .01). Neonatal exposure diagnoses did not
differ over time in region 5 (Z: 0.84, P = .40). After controlling for region differences, the NAS
IR trend was statistically significant (χ2MH=99.01, 6 d.f., P < .0001).
During this time period the diagnosis of cocaine exposure decreased (Z: 3.62, P = .0003)
from 1.77 to 0.74 per 1,000 live births. Region-specific cocaine exposed diagnoses significantly
decreased over time in regions 5 (Z: 2.49, P = .013) and 6 (Z: 3.02, P = .003). These diagnoses
did not significantly decrease between 2007 and 2013 for regions 1 (Z: 0.27, P = .786), 2 (Z:
1.20, P = .229), 3 (Z: 1.46, P = .144), and 4 (Z: 0.733, P = .4636). After controlling for regional
variation, cocaine diagnosed exposure decreased over time (χ2MH=17.77, 6 d.f., P = .0007).
Diagnosis of hallucinogenic agent exposure did not significantly change over time (Z: -1.61, P =
.11).
Controlling for year, the amount of NAS cases differed significantly by birthing hospital
(n=30, χ2MH=906.67, 29 d.f., P < .0001). Between 2007 and 2013, the average hospital rate of
NAS diagnoses ranged from zero to 36.76 per 1,000 live births. During the study period, the 3
level III neonatal intensive-care units (NICUs) in WV delivered the following number of infants
diagnosed with NAS: 239 (1.2%), 150 (2.04%), and 373 (2.95%).
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Characteristics by NAS Diagnosis
Infants with a primary or secondary NAS diagnosis were more likely to exhibit
respiratory issues (χ2: 366.01, 1 d.f., P < .0001), feeding difficulties (χ2: 95.38, 1 d.f., P < .0001),
and seizures (χ2: 92.50, 1 d.f., exact P < .0001), compared to newborns without a NAS diagnosis.
These babies were also statistically more likely to be diagnosed with narcotics (χ2: 903.56, 1 d.f.,
exact P < .0001), hallucinogens (v: 11.77, 1 d.f., exact P = .0156), and cocaine (χ2: 113.53, 1 d.f.,
exact P < .0001) exposures than newborns without NAS. Comparatively, newborns diagnosed
with NAS had a longer length of stay (z: 57.77, 1 d.f., P < .0001), and were more likely to have
Medicaid insurance (χ2: 753.01, 3 d.f., P < .0001) (see Table 2.1).
2.4 Discussion
NAS and Exposure
The current study was the first to assess the incidence rate (IR) of NAS throughout the
predominantly rural state of WV. Between 2007 and 2013, the statewide rate of NAS diagnosis
increased over 4-fold. Although the upward trend was expected, the increase of NAS rates over
time was markedly higher in WV compared to national estimates.[16, 17] In 2009, WV’s NAS
IR was 3.5 times as high as nationwide rates (3.4 vs. 11.8 NAS per 1,000 live births).[17] The
same year, Ohio reported a NAS rate of about 5 cases per 1,000 live births and Vermont found a
NAS and opioid exposure rate of 24.2 per 1,000 live births.[92, 93] Vermont’s rate was likely
higher because they utilized a different case definition (i.e., all opioid exposed infants and/or
infants diagnosed with NAS were considered cases).[92] In 2010, WV’s NAS IR was over 3
times as high as nationwide estimates (14.7 vs. 4.8 NAS per 1,000 live births).[16] In 2011,
WV’s statewide NAS IR was 16.9 per 1,000 live births, which was higher than the national
average (3.4) and various state-specific rates in Tennessee (8.5), Kentucky (13.2), and Florida
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(7.52) in the same year.[16, 94] In 2012, WV’s NAS IR was 3.7 times higher than nationwide
rates (5.8 vs. 21.4 NAS per 1,000 live births).[16]
Between 2007 and 2013, the current study showed the rate of neonatal substance
exposure diagnosis increased over 4-fold for narcotics while neonatal cocaine exposure
decreased over 2-fold and hallucinogens remained stable. Further examination of a potential shift
in maternal drug use is indicated. Although national estimates of neonatal substance exposure via
the ICD-9-CM diagnostic codes 760.7x are not currently available, Ohio reported similar patterns
to WV between 2004 and 2011 of neonatal narcotic, cocaine, and hallucinogen substance
exposure.[93] In addition, nationwide data during this time period showed that opioid-related
overdose deaths and substance abuse treatment admission discharges vastly increased, while
these estimates decreased for cocaine-related deaths and treatment admissions.[95, 96] A drastic
increase in the environmental availability of prescription narcotics (i.e., increased prescriptions
written and dispensed, greater social acceptability for non-medical use, and pharmaceutical
marketing) could explain the increase in neonatal opioid and other noxious substance exposure
resulting in the quadrupled NAS rates.
Geographic and Time Trend Variations
In the present study, NAS rates differed by WV residential sub-state SAMSHA regions,
with the highest occurring in the southeastern part of the state. This finding is congruent with
other data, as age adjusted death rates due to drug poisoning per 100,000 WV residents was the
highest in the south between 1999 to 2009.[97] In addition, other characteristics associated with
substance use and obstetric/neonatal health outcomes were found to be higher among residents
from the respective area, compared to the rest of the state. According to the 2010 WV Vital
Statistics, the highest percent of low birthweight babies, mothers less than 18 years of age at
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delivery, no prenatal care, and congenital anomalies occurred among residents from the
southeastern regions of WV.[77] This area also had the highest prevalence of any mental illness
in the past year (18 or older), nonmedical use of pain relievers (12 or older), residents without a
high school degree, percent of drug/narcotic-related arrest, and lowest weighted average median
household income.[71, 98, 99]
Compounding the described challenges, treatment facilities are unevenly available
throughout WV. Throughout the study period, there were 9 WV federally funded (methadone or
buprenorphine) opioid maintenance therapy (OMT) facilities that accepted pregnant women for
the recommended OMT treatment, of which only 1 was located in the southeastern area of WV
(see Figure 3.1).[100] Although OMT can result in NAS, the therapy is preferred over continued
illegal substance use in order to improve obstetric and neonatal outcomes via decreased maternal
illicit behaviors, improved prenatal care, and eliminated acute intoxication and withdrawal
during pregnancy.[89, 101] Therefore, higher regional occurrence of obstetric and neonatal
health outcomes could be linked to the lack of available treatment options for this vulnerable
population.[101, 102]
An examination of time trends by region showed that incidence of NAS rates first rose in
the Eastern Panhandle and during subsequent years rose throughout WV, with the highest IR in
the southern regions of the state. The high NAS rate in the Eastern Panhandle at the beginning of
the study period (i.e., 2007) may explain why NAS IR trends were not statistically significant in
region 2. Aside from the inherent risk factors mentioned above, this trend could have resulted
from potential drug trafficking routes and increased medical awareness. The Office of National
Drug Control Policy has identified 11 southern WV counties (9 located in region 6 and 2 in
region 5) as high-intensity drug trafficking areas, due to the Appalachian drug abuse
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problem.[103] Geographically, US 19 corridor is also a high-intensity drug trafficking area
because of the flow of prescription pills from Florida into the Appalachian area.[104] In addition,
WV is located in the middle of drug trafficking routes on major highways connecting the west
and southwest regions to the profitable East Coast markets.[105]
It is also likely that a significant increase in medical awareness has led to a higher rate of
NAS diagnoses over time. There could be more accurate diagnosis in areas around major
medical centers and hospitals located on the Ohio, Maryland, and Virginia borders. Although
heightened provider awareness of NAS and its signs/symptoms could contribute to the increasing
trend, the opioid epidemic documented in the literature, along with the current study finding of
increased neonatal substance exposure, makes this possibility less likely.
Along with regional differences, NAS IR varied by hospital. High risk patients are more
likely to deliver at the closest hospital capable of dealing with fetal and/or maternal
complications. During the study period, the level III NICU hospitals, those capable of treating
NAS diagnosed infants, had comparatively high NAS cases per 1,000 live births. The top 11
hospitals with average NAS IRs above 20 per 1,000 live births were located in the southeastern
regions of the state (i.e., in regions 2, 5, and 6), resulting in more accessibility to patients
residing in this area.
There was no clear pattern of regional differences among diagnosed neonatal substance
use exposure. In addition, NAS rates were greater than substance exposure rates, thus they did
not mirror each other. These findings indicate WV greatly underutilizes neonatal substance
exposure codes (i.e., the 760.7x ICD-9-CM codes). NAS-related reporting and surveillance
would be improved if practitioners diagnosed every NAS infant with respective exposure codes
and if policy recommendations included adding NAS to WV’s list of reportable diseases,
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implemented an interoperable insurance/hospital system, and created a statewide standardized
surveillance system to track NAS. In 2013, Tennessee was the first state to establish a successful
statewide real-time tracking surveillance system for NAS.[106] In the first year, they identified
over 900 newborns with NAS, two-thirds originating from mothers who were legally consuming
prescription medications while pregnant and most of whom resided in Appalachian counties.
NAS Associated Impact
The significant associations between NAS and neonatal clinical conditions (i.e.,
respiratory issues, feeding difficulties, and seizures), as well as NAS and substance exposure
(i.e., narcotics, hallucinogens, and cocaine) are consistent with existing research.[11, 92, 107] As
expected, infants diagnosed with NAS were also more likely to be covered by Medicaid and have
a longer hospital length of stay.[17, 107] The average hospital length of stay for NAS infants in
WV was 12.7 days, shorter than the average national estimate of 16 days. In contrast, the WV
average length of stay for newborns not diagnosed with NAS was 2.86 days, equivalent to the
US average of 3 days.[17]
As highlighted by associated neonatal comorbidity and longer hospital length of stay, the
impact of NAS to WV is substantial. Addressing this high cost and medical resource intensive
public health issue involves a multi-faceted approach to policy, interventions, and evaluation of
systematic efforts. Rural pregnant women with substance use disorders have unique treatment
needs.[82] Future research is needed to identify optional substance use treatment and potential
barriers to treatment access for this population.
Limitations
There are inherent limitations to using hospital discharge data. The HCA-UB data was
created for payment use, therefore it is restrictive in its use to research a statewide health
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condition. Hospital charges might not translate to actual costs because charges are often
negotiated by payers and costs can be separated via mother and infant claims, thus a cost analysis
was not conducted in the current study. In addition, hospital billing practices could change over
time. Overall, population-based surveillance is dependent on accurate and homogenous statewide
coding from documenting a condition in the medical records to being coded in the discharge
abstract. Furthermore, hospital billing data may underreport the diagnosis of NAS and neonatal
substance exposure, especially when not all newborns are drug screened and exposure status is
based on maternal self-report.[17, 92, 109]
Statewide identifiable data were unavailable, therefore hospital admissions/discharges
rather than individual patients were the units of observation. Although unlikely, NAS discharges
may result in duplication when the same patient (i.e., a newborn) has multiple hospital
admissions. This would potentially underestimate NAS rates because it could increase the total
population (i.e., denominator), while the NAS cases (numerator) would remain constant as this
condition is likely to be diagnosed at the first hospital admission. These potential problems are
driven from the study design and data source, thus solutions are limited and constraints may be a
limitation of the data. Although data limitations exist, the HCA-UB is retrospectively the best
approach to obtaining a statewide NAS rate of WV residents because it is the only data source
that currently captures all insurance types. Strictly using Medicaid data would overestimate NAS
rates, as it would mostly capture the at-risk population.[109]
Conclusion
The present study showed that in a state where over half of the residents live in rural
areas[76], newborns with NAS were more likely to present other clinical conditions, experience
longer hospital length of stay, and be insured by Medicaid. In addition, WV statewide neonatal
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diagnosis rates of both NAS and narcotic exposure have markedly increased. Narcotic substances
affecting fetuses or infants via placenta or breastmilk were diagnosed less often than NAS,
indicating underreporting of this neonatal exposure diagnosis. This finding is important because
in practice the ICD-9-CM NAS diagnostic code is not broken down by drug-specific causes and
therefore these neonatal exposure codes should be utilized in order to examine drug-specific
trends. Surveillance epidemiologists should take this finding into consideration when studying
neonatal substance exposures.
The current study provides further public health justification to increase efforts aimed at
reversing the NAS-associated burden within rural areas. Public health interventions or treatment
programs for this vulnerable population are especially important in the southeastern region of
WV. West Virginia providers and medical coders need to better utilize the neonatal substance
exposure codes (ICD-9-CM 760.7x). In order to eliminate inherent limitations related to the
currently available hospital discharge data, the state needs to provide standardized patient-level
identified data for future public health research and quality improvement initiatives.
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Chapter 3
Exposure to substance use in utero, risk of neonatal abstinence syndrome, and
antenatal correlates: A retrospective medical chart review
Abstract
Objective: Although opioid in utero substance exposure is the primary cause of neonatal
abstinence syndrome (NAS), other non-opioid substances have been linked to NAS diagnoses.
The risk of NAS and NAS requiring pharmacological treatment among non-opioid exposures is
unknown. Method: A retrospective medical chart review was analyzed for 476 mother-infant
antenatal exposed dyads who delivered between January 1st 2009 and March 3rd 20014, with 137
NAS diagnoses (ICD-9-CM 779.5), and 75 diagnoses that required pharmacological treatment.
Risk of NAS/NAS requiring treatment and odds of NAS, controlling for potential confounders
via a logistic regression, were observed among drug class-specific exposure groups
operationalized via neonatal meconium and umbilical cord tissue drug screens. Results: The
absolute risk of NAS was 29% and risk of NAS requiring treatment was 54%. Variations existed
between drug class exposures, specifically opioid exposure (poly and single) had the highest risk
of NAS and sedative-only exposure had the highest risk of NAS requiring treatment. After
controlling for potential biopsychosocial confounders, odds of NAS was significantly higher for
opioid exposures [single: OR=3.72, 95% CI: 1.54, 9.98, poly: OR=3.52, 95% CI: 1.13, 10.98].
Number of prenatal care visits and maternal opioid maintenance therapy enrollment were
independent risk factors for NAS diagnosis. Conclusion: A NAS diagnosis most commonly
occurred with opioid exposures, though risk among non-opioid exposures ranged from 11% to
33%. There are no drug-specific diagnostic criteria or treatment protocols for neonatal substance
withdrawal. Future examination of non-opioid based NAS protocols and studies regarding NAS
severity with sedative in utero exposures are warranted.
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3.1 Introduction
Intrauterine exposure, to nearly any psychoactive licit or illicit substance, can lead to
neonatal drug-related adverse outcomes or inadequate fetal growth which are major factors in
infant disability, and, in severe cases, mortality.[22, 110] Psychoactive drugs readily transfer
from the mother to her neonate through the trans-placental passage, which can cause early
disrupted fetal programming and developmental processes via various pathophysiologic
pathways.[22, 110] In 2009, a multi-hospital study in WV drug tested neonatal umbilical cord
tissue specimens and found 19.2% of neonates were exposed to any substances (roughly 1 in 5).
[4] Specifically, 5.4% and 1.8% of the total population tested positive of opioids and methadone.
The same year, nationally representative data indicated 0.56% of mothers used and/or were
dependent on methadone or any other opiate analgesic during pregnancy. [17] Although
substance use among pregnant women is prevalent nationwide, WV’s estimates outnumber the
national averages indicating a significant public health issue.[1, 17] Due to the increase in
incidence and geographic distribution of substance use in pregnancy, neonatal abstinence
syndrome (NAS) is an increasingly concerning public health issue.
NAS is a constellation of central nervous system, metabolic vasomotor, respiratory, and
gastrointestinal disturbances a neonate experiences resulting from drug withdrawal following
delivery.[11, 12] Between 2000 and 2012, the nationwide incidence of NAS increased nearly
500% from 1.2 to 5.8 per 1,000 hospital births per year.[16, 17] In 2009, it was estimated that
each hour a baby was born diagnosed with drug withdrawal in the United States.[17] Along with
the health ramifications of NAS, associated fiscal consequences and strained health care
resources result from treating this diagnosis. In 2009 the US public health and medical cost
resulting from babies born with drug withdrawal was between 70.6 and 112.6 million
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dollars.[18] The average length of stay in hospital care for babies born from opioid dependent
women is 16 days, which is dramatically longer than the average of 3 days for healthy
neonates.[17]
Higher financial impact and longer neonatal hospital length of stay reflect the overall
severity of NAS. NAS severity is dependent on numerous factors that include poly-drug use,
gestational age of substance use, maternal smoking, psychiatric medications, other obstetric
outcomes, and genetic factors.[112, 113] If neonates have severe enough NAS they will be
pharmacologically treated with an opiate or opioid based medication.[11]
NAS most commonly occurs among neonates exposed to licit or illicit opioids during
pregnancy, although other substances can induce similar signs and symptoms of withdrawal and
therefore results in NAS diagnosis.[17, 22] Although a lack of literature exists regarding NAS
and non-opioid exposures, especially among a general substance using maternal population,
NAS symptomatology has been linked to alcohol [23-25], nicotine [26-29], cocaine[30-32],
phencyclidine (or PCP) [33], methamphetamines [34], benzodiazepines[35, 36], and other
psychotropic medications[37-40].
Identification of NAS diagnoses with non-opioid in utero exposures are problematic
because generally there are no drug-specific diagnostic criteria for withdrawal nor are there drugspecific treatments for nonopioid-exposed neonates. The scoring system utilized to diagnose,
assess severity, and determine treatment protocols is based off opioid withdrawal symptoms of
term babies, when in fact drug-specific neonatal withdrawal is likely to differ based on the
substance of exposure and the gestational age of the neonate.[22, 41] In addition, the most
common first-line treatment of NAS is morphine or methadone.[11] Opioids might not be the
choice of treatment in non-opioid exposed neonates, especially with the rising concern of
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iatrogenic NAS. Iatrogenic or hospital-induced NAS is when the syndrome is inadvertently
induced via medical treatment, as opposed in antepartum substance exposure.
The purpose of the current study is to evaluate the risk of both NAS and NAS-requiring
pharmacological treatment among neonates of substance-using women, and to determine
whether cases differ based on drug class-specific exposures. In addition, the odds of NAS were
estimated while controlling for potential confounders.
3.2 Methods
We conducted a retrospective cohort study of mother-infant dyads exposed to antenatal
substance use. Specifically, a retrospective electronic medical chart review was conducted at a
major birthing center located in north-central WV between January 1, 2009 and March 3, 2014.
Ethical approval for the current study was obtained from the Institutional Review Board at the
academic institution of the authors.
The following inclusion and exclusion criteria were adopted in order to assemble a
retrospective cohort of neonates who were exposed to substances in utero. Women who had an
active drug use diagnosis at delivery (ICD-9-CM: 303.9x, 304.x, 305.x, 648.31, 648.32, 649.01,
649.02), any positive urine drug screen in the nine months prior to delivery, were prescribed
buprenorphine or methadone at delivery admission prior to giving birth (eRx codes: 4952, 4953,
4954, 10546, 87402, 87403, 87408, 87409, 135736, 190788, 201165, 201166, 1000152,
1000430, 1000431, and 1000555), or who delivered a neonate diagnosed with NAS (ICD-9-CM:
779.5) were included in the study. Electronic prescribing codes for buprenorphine or methadone
during the delivery admission are unique indicators of a pregnant woman currently enrolled in an
opioid maintenance therapy (OMT).[61] Women younger than 18 years of age at delivery and
neonates younger than 28 weeks gestational age were not included in the study population.
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Mother-infant dyads were created by matching the woman’s delivery admission with the
neonate’s hospital admission. The sample was limited to the first singleton live birth (ICD-9-CM:
V27.0) of women who met the inclusion criteria.
Mother-infant dyads were excluded if they did not deliver at the study hospital (n=5), the
neonatal electronic medical records weren’t transferred in its entirety from the old to the new
electronic health record system at the study hospital (n=2), the neonate expired during the same
delivery admission (n=8), or if the neonate was deemed to have iatrogenic NAS (n=15).
Neonates at risk for iatrogenic NAS are those born with an intraventricular hemorrhage (ICD-9CM 772.1x), periventricular leukomalacia (779.7), necrotizing enterocolitis (777.5x),
spontaneous intestinal perforation (777.6), or bronchopulmonary dysplasia (770.7).[17] The
etiology of withdrawal is different between hospital-induced and intrauterine exposed neonates;
therefore, neonates at risk for iatrogenic NAS were excluded from the study. A total of 29
mother-infant dyads were excluded from the study, as one neonate expired during the hospital
admission and met the criteria for iatrogenic NAS.
After patients were selected for study inclusion and easily accessible clinical parameters
were collected via a hospital decision support analyst, medical charts were critically reviewed.
Medical notes in each patients’ charts were read to determine the presence of biopsychosocial
variables of interest. Manually-abstracted data were entered and stored in a HIPAA compliant,
web-based, electronic data capture application called Research Electronic Data Capture
(REDCap). ICD-10-CM codes were not in use during the study period; therefore, all diagnostic
indictors where derived from ICD-9-CM codes.
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Exposure
In utero substance exposure was defined as mutually-exclusive drug class grouping via
non-invasive umbilical cord tissue and meconium biological drug screens conducted at delivery.
To determine absolute risk of NAS diagnosis and NAS requiring pharmacological treatment, a
seven category drug class-specific exposure variable was created that included opioids-,
cannabis- stimulants-, and sedatives-only, poly-substances with opioids, poly-substances without
opioids, and non-positive test results. Non-positive results do not exclude the possibility of
prenatal substance use; they simply indicate that the drug or metabolite in the specimen did not
meet the concentration cutoff required for a positive screen (see Appendix E). In addition,
exposure to alcohol, nicotine, and caffeine was not determined as these substances are not
included in the meconium and umbilical cord tissue drug screen panel.
To then estimate the odds of NAS diagnosis among neonates of substance using women,
a five category drug exposure variable was created that includes opioids-, cannabinoids-only,
poly-substances with opioids, other, and non-positive. ‘Other’ includes neonates singularly or
poly-exposed to drug classes other than opioids and cannabinoids. Non-positive results are
defined in the paragraph above. Specific drugs that are categorized in the five exposure groups
are outlined in Table 3.1. None of the neonates in the sample tested positive (meconium or
umbilical cord tissue) for phencyclidine (i.e., PCP), and thus it was not included in the drug
grouping.
Neonatal specimens were collected for medical purposes only and sent for analysis to
Associated Regional and University Pathologists (ARUP) laboratories in Salt Lake City, Utah.
Universal umbilical cord tissue drug screens have been initiated on all neonates at the study
birthing center from since March 1 2013. Prior to the initiation of universal cord-tissue drug
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screens, meconium drug screens were conducted on all neonates suspected of substance exposure
(defined in the outcome section above). Meconium is the first stool that the neonate passes that
begins to form at 12-16 weeks gestation, prior to the appearance of breastmilk- or formula-based
stool.[114] Therefore, meconium acts as a reservoir for drug and metabolite compounds and is a
reliable specimen in which to assess in utero substance exposure.[114] Umbilical cord tissue
specimen is thought to detect substance exposure during the same range of gestational ages as
meconium. In addition, umbilical cord tissue is viewed as an alternative to meconium drug
screening because both have similar drug detection abilities and have an agreement above 90%
for amphetamine, opiates cocaine, cannabinoid, and phencyclidine tests.[49, 50]
Although screening umbilical cord tissue is a more recent technique and less is known
about the disposition of drugs in the specimen, clinicians often prefer its use over meconium.
Meconium collection is often delayed compared to umbilical cord tissue collection because it
typically takes up to three days after birth to pass, or often longer among premature
neonates.[115, 116] Additional drawbacks to meconium testing verses umbilical cord tissue
testing are availability and compromised samples. Meconium may not be available if passed in
utero or during birth and it can be compromised if it is diluted with other substances (e.g., urine)
or if there is not enough specimen for confirmation testing.[45] Both meconium and umbilical
cord tissue testing are preferred over maternal and neonatal urine drug screens, as they have a
longer detection window.[45]
Meconium samples (at least 4 grams) were screened via the hospital’s testing protocol by
enzyme-linked immunosorbent assay (ELISA) to identify the drug class (i.e., cannabinoids,
cocaine, opiates, phencyclidine, amphetamines, barbiturates, methadone, benzodiazepines, and
propoxyphene). Any positive results were followed by confirmation of a fully validated gas
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chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry.[117]
Drug classes screened via umbilical cord tissue specimens included opioids, stimulants,
sedatives-hypnotics, cannabinoids, and phencyclidine. Specimens of umbilical cord tissue (at
least 6 inches) were tested via a ‘gold standard’ of liquid chromatography-time of flight mass
spectrometry and ELISA.[118, 119] Sensitivity and specificity of the ELISA compared to the
mass spectrometric method were 91% and 98%, respectively.[120]
Outcome
The outcome of interest for this study was the incidence of neonatal abstinence syndrome
(NAS) among substance-exposed infants. The outcome was defined as ‘present’ if a neonate had
a primary or secondary diagnosis of NAS (ICD-9-CM code 779.5: Drug withdrawal syndrome in
newborn) and ‘absent’ if there was not a NAS diagnosis in the neonate’s medical record. The
withdrawal diagnosis does not specify the drug exposure that resulted in the neonatal withdrawal.
NAS diagnosis and severity was initially assessed via the modified Finnegan Scale.[41]
Neonates exposed or suspected of exposure to in utero substances were evaluated prior to
feeding, every 2 to 4 hours after birth. Suspected neonates are those that are born to mothers with
a history of drug use, minimal to no prenatal care, and unexplained placental abruption or
premature labor, and are born with unexplained neurological complications, unexpected
intrauterine growth retardation, and evidence of intoxication (e.g., positive maternal urine drug
screen during pregnancy) and/or NAS signs and symptoms.[48] NAS was diagnosed when a
neonate scored ≥8 during two consecutive screenings. Non-pharmacologic treatment occurred at
the onset of all NAS diagnoses (i.e., kangaroo care, swaddling, high caloric diet, and a lowstimuli environment). If NAS was more severe (i.e., neonates with a score of ≥12 or greater on
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three consecutive occasions or a combined score of ≥28) than pharmacological treatment of
morphine sulfate drops were administered.
Covariates
To calculate the least-biased estimate of the effect of in utero substance exposure on the
incidence of NAS, confounding was explored and controlled in the analysis. Biologic,
psychological, and socioeconomic factors of the women and/or neonates associated with NAS
and maternal substance use were specified using the biopsychosocial model as a theoretical
framework as shown in Figure 3.1.[70] This model aims to assess health-related outcomes via a
holistic multi-faceted approach.
Biological
Biological factors likely to influence the substance to which the fetus was exposed and
neonatal expression of drug withdrawal include maternal age, nulliparous status, current
gravidity, pre-pregnancy maternal body max index, delivery type (cesarean or vaginal), neonatal
gestational age (weeks), and neonatal growth parameters of head circumference (centimeters),
length (centimeters), and weight (grams) at delivery.[121-123] Delivery type was categorized as
a binary variable of cesarean or vaginal delivery.
Psychological
The aggregated presence of maternal psychological-related diagnostic codes given at
labor and delivery were utilized as a psychological factor in the biopsychosocial model.[124]
This variable was categorized as ‘present’ if the mother was diagnosed with a mood disorder
(IDC9-CM: 293.83, 296.90, 296.99), anxiety disorder (293.84, 300.00, 300.02), schizophrenia
(295.30, 295.62, 295.90), major depressive disorder (296.20, 296.23, 296.25, 296.30, 296.32,
296.33, 296.36), bipolar (296.40, 296.42, 296.50, 296.53, 296.60, 296.7, 296.80, 296.89),
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unspecified psychosis (298.9), panic disorders (300.01), conversion disorder (300.11),
agoraphobia (300.21), obsessive-compulsive disorders (300.3), dysthymic disorder (300.4),
antisocial personality disorder (301.7), borderline personality disorder (301.83), other isolated or
specific phobias (300.29), unspecified nonpsychotic mental or personality disorders (300.9,
301.9), and other pervasive developmental disorders (299.80).
Socioeconomic
Socioeconomic factors included as covariates consisted of maternal years of education at
delivery, Medicaid insurance status and metropolitan residence.[125, 126] Medicaid insurance
status was an artificially dichotomized variable of ‘Medicaid’ or ‘other.’ Living in a metropolitan
area was defined via a patient’s county of residence and the Office of Management and Budget’s
delineation.[127] A metropolitan area was defined as having at least one urbanized area (10,000
or more inhabitants) of 50,000 or more residents. Rural-Urban 2013 Continuum Codes were
utilized to match each patient’s county of residence to the appropriate categorization of
metropolitan or nonmetropolitan status.
Biopsychosocial Unions
Covariates operationalized as biopsychological included number of spontaneous
abortions, maternal history of substance use or mental health treatment, maternal opioid
maintenance therapy enrollment, and history of chronic pain.[126, 128] Spontaneous abortions
were defined as a non-therapeutic miscarriage before 20 weeks gestational age. Maternal opioid
maintenance therapy during pregnancy was captured as a binary (yes/no) variable indicating
whether the women were enrolled in buprenorphine or methadone maintenance treatment.
History of substance use or mental health treatment and chronic pain are both binary variables
(yes/no). The number of prenatal care visits during pregnancy was categorized as a bio-
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socioeconomic variable.[125] Psycho-socioeconomic variables include marital status, whether
the patient’s family visited the hospital during labor and delivery admission (yes/no), reported
familial support (yes/no), documented signs of physical abuse at hospital admission
(yes/no).[123, 125, 129] Marital status was categorized as married, single, or other; with other
including mothers who are divorced, legally separated, or widowed. Maternal use of selective
serotonin reuptake inhibitors (SSRIs) and the self-reported number of cigarette packs smoked per
day were represented by all three areas of the biopsychosocial model.[130] Packs of cigarettes
smoked per day was a continuous number that ranged between zero to five packs.
Statistical Analysis
The incidence of NAS and NAS requiring pharmacological treatment was calculated and
the number of cases, corresponding risk, and 95% confidence intervals (CI) are reported by drug
exposure groups. To determine significant differences between substance groups, the Chi-square
test was conducted with the level of significance at alpha less than or equal to .05.
Descriptive statistics were computed and reported as frequencies and percentages for
categorical variables and as means and standard deviations for continuous variables (or median
and interquartile ranges for non-normally distributed data). Maternal and neonatal characteristics
by NAS diagnosis were assessed via Cochran-Armitage trend test, Fisher’s exact, or Chi-square
test for categorical variables and student’s t-test and Wilcoxon rank-sum test for continuous
measures.
Potential confounders were identified via the change-in-estimate method. That is, if
covariates changed the effect estimate (i.e., odds ratio) of the neonatal in utero substance
exposure variable by 10 or more percent it was included in the regression model.[73] The
adjusted logistic regression model controlled for maternal history of chronic pain (referent was
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no history), history of drug/mental health treatment (referent was no history), number of prenatal
care visits, cigarette packs per day, whether the mother’s family visited her during the labor and
delivery hospital admission (referent was no visit), whether the mother reported family support at
hospital admission (referent was no support), and the mother’s pre-pregnancy body mass index.
All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, North Carolina).
3.3 Results
Of the 543 mother-infant dyads who met the inclusion criteria, 476 (88%) had a
meconium or umbilical cord tissue drug screen conducted at delivery and were therefore
included in the analysis. Of the neonates included in the analysis, 137 (29%) were diagnosed
with NAS, and of those diagnosed with NAS, 75 (55%) were pharmacologically treated. Based
on drug screen results, 110 (23%) neonates were defined as opioid-only exposed, 94 (19.8%)
were defined as cannabis-only exposed, 75 (15.8%) were defined as poly-substance including
opioids exposed, 31 (77) were positive for ‘other’ drug exposure, and 166 (35.9%) were nonpositive. Specifically, 9 (1.9%) of the neonates categorized as ‘other’ exposure tested positive for
stimulants-only, 15 (3.2%) were sedatives-only, and 7 (1.5%) were exposed to poly-substances
without opioids.
NAS and Pharmacological Treatment by Drug Class Exposure
The risk of NAS was 29.2% and, of those diagnosed with NAS, the risk of being
pharmacologically treated was 54%. Categorized by drug class-specific exposures, opioid-only
exposed neonates had an absolute risk of NAS of 45.5% and of those 54% were
pharmacologically treated. Cannabis-, stimulant-, and sedative-only had an absolute risk of NAS
of 12.8%, 11.1%, and 33.3% and within the exposure categorization 33.3%, and 80% were
pharmacologically treated for NAS, respectively. Poly-substance with opioids exposure had an
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absolute NAS risk of 41.3% and of those diagnosed with NAS, 67.7% were pharmacologically
treated. Poly-substance exposure without opioids had an absolute NAS risk of 28.6% and of
those diagnosed with NAS, 50% were pharmacologically treated. Neonates of substance-using
mothers who did not screen positive had an absolute risk of NAS of 33.8% and of those
diagnosed with NAS, 47.4% were pharmacologically treated.
Maternal and Neonatal Characteristics
The average maternal age was 26.1 years (SD= 5.1), median years of education
completed was 12 (IQR 11, 13), 8 (1.7%) mothers exhibited signs of physical abuse, 79 (17.3%)
had a history of chronic pain, the median amount of packs of cigarettes smoked per day were 0.5
packs (IQR 0.2, 1.0), 60 (12.7%) were prescribed SSRIs during pregnancy, and 100 (21.0%)
were diagnosed with a mental health condition. A majority of women were single (304; 64.7%),
insured by Medicaid (375; 78.8%), lived in metropolitan defined areas (256; 54.6%), had family
visit them during the labor and delivery hospital admission (374; 91.7%), were enrolled in opioid
maintenance therapy during pregnancy (209; 44%), and had a history of drug and/or mental
health treatment (268; 57.0%). About a third of the women were nulliparous (37.2%), the median
gravidity of 2 (IQR= 2, 4), and the median spontaneous abortions of 0 (IQR= 0, 1). Maternal
characteristics of the delivery of interest included an average of 8.8 (SD=5.7)
obstetrics/gynecology visits during pregnancy, mode of delivery (300 or 63% vaginal and 176 or
37% cesarean), and maternal pre-pregnancy BMI of 22.6 (IQR= 19.7, 27.5). The slight majority
of neonates were male (240; 50.4%) and neonatal growth parameters include: gestational age of
38.1 weeks (IQR= 36.9, 39.2), head width of 33 centimeters (IQR= 31.5, 34), length of 47.6
centimeters (SD= 3.8), and weight of 2,816.7 grams (SD=620.8).
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Prenatal Substance Exposure and NAS
Neonates whose meconium or umbilical tissue tested positive for substances, who were
born to women who had a history of chronic pain, a history of drug or mental health treatment,
were enrolled in opioid maintenance therapy during pregnancy, and who were born to women
who had fewer prenatal visits were significantly more likely to develop NAS than their
counterparts.
Neonates exposed to opioids-only were nearly three times as likely [unadjusted OR =
2.81; 95% CI: 1.67, 4.73] to be diagnoses with NAS compared to neonates not positively
screened for drug exposure. Poly-substance with opiate in utero exposure and neonates with
other substance exposure were 137% [unadjusted OR = 2.37; 95% CI: 1.32, 4.26] and 17%
[unadjusted OR = 1.17; 95% CI: 0.49, 2.83] more likely to be diagnoses with NAS than neonates
not positively screened for drug exposure, respectively. Cannabis-only exposed neonates were
51% [unadjusted OR = 0.49; 95% CI: 0.24, 0.99] less likely to be diagnoses with NAS compared
to neonates not positively screened for drug exposure.
When controlling for biopsychosocial factors, the association between in utero substance
exposure and NAS persisted for opioid-only and poly-substance with opioid exposed neonates.
The adjusted odds of NAS among opioid-only and poly-substance with opioid exposed neonates
was 272% [OR = 3.72; 95% CI: 1.54, 8.98] and 252% [OR = 3.52; 95% CI: 1.13, 10.98] greater
than the odds of NAS among neonates without a positive drug screen, respectively. Adjusted
biopsychosocial factors significantly associated with the odds of NAS included maternal
enrollment in opioid maintenance therapy at pregnancy and number of prenatal care visits. For
every increase in number of prenatal care visits, the odds of delivering a neonate diagnosed with
NAS decreased 8% [OR = 0.92; 95% CI: 0.86, 0.99]. Neonates of mothers enrolled in opioid
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maintenance therapy were more than six times [OR = 6.54; 95% CI: 2.30, 18.57] as likely to be
diagnosed with NAS compared to neonates born to mothers not enrolled
3.4 Discussion
Primary Findings
The study cohort of neonates who were exposed to substances in utero had a high
absolute risk of NAS (29.2%) and of those diagnosed most were pharmacologically treated
(54.0%). Risk of NAS significantly varied among drug exposure type. The highest risk occurred
with opioids-only and poly-substances with opioids, and the lowest risk of occurred within the
stimulants-only exposure group. Of the neonates diagnosed, the highest drug class exposure
requiring treatment for NAS ranged from sedatives-only as the highest to cannabis-only and
stimulants-only as the two lowest exposure groups. Only one neonate was diagnosed with NAS
and had a stimulants-only exposure, therefore this risk statistic cannot be empirically evaluated.
After controlling for biopsychosocial covariates, neonates exposed to opioids-only and
poly-substance with opioids were significantly more likely to be diagnosed with NAS. The
covariates that remained significant in the fully adjusted model include number of prenatal care
visits and maternal opioid maintenance therapy enrollment. Greater number of prenatal care
visits was associated with a lower likelihood of a being diagnosed with NAS. This finding is
expected as increased prenatal care is associated with improved maternal and neonatal health
outcomes.[109, 131] Although increased screening will likely increase the chance of a neonate
being identified and diagnosed, the benefit of prenatal care likely outweighs the potential
influence of increased detection. As expected, neonates of mothers enrolled in OMT during
pregnancy had a higher likelihood of being diagnosed with NAS. Women in OMT are given
buprenorphine or methadone during pregnancy to stabilize their opioid dependency and
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eliminate antenatal withdrawal. In utero exposure to both buprenorphine and methadone can
result in NAS.[132]
Risk Comparisons with Other Studies
Risk and severity of NAS differentiate between studies via the study population (e.g.,
only mothers enrolled in OMT or a general at-risk population) and operationalization of in utero
substance exposure. Risk of NAS and NAS requiring pharmacological treatment typically are
studied among infants of opioid dependent mothers and/or among women who filled a
prescription of opioids during pregnancy. Between 1998 and 2009, 5.6% of women who were
prescribed narcotic pain medication for more than one month during pregnancy delivered at
newborn diagnosed with NAS.[133] Medicaid data revealed that infants born to women who
filled a prescription for the same length of time during pregnancy had a 2.4% risk of being
diagnosed with NAS.[61] This risk increased when opioid prescriptions were filled within the
last 90 days before delivery and in the presence of other risk factors, including a documented
history of opioid drug misuse/dependence, history of alcohol/non-opioid misuse, use of other
psychotropic medications in the third trimester, and a documented smoking history.
In addition to various study populations, risk of NAS and NAS requiring treatment
differentiate between infants exposed to heroin throughout pregnancy verses those exposed to
OMT. Among neonates exposed to heroin throughout gestation, 42% were diagnosed with NAS
and 18% required pharmacological treatment.[134] Another study reported 27% of infants born
to mothers on methadone maintenance therapy were diagnosed with NAS.[109] Additionally, in
2010 a randomized control trial compared the effectiveness between buprenorphine and
methadone OMT among 175 opioid dependent pregnant women enrolled in therapy, with respect
to neonatal growth parameters and NAS diagnosis, treatment, and length of stay indicators.[132]
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Results indicated both medications were acceptable OMT options and that the risk of NAS
requiring treatment was 47% and 57% among infants born to mothers on buprenorphine and
methadone maintenance therapy during pregnancy, respectively.[132]
There is a lack of research of NAS and NAS requiring pharmacological treatment among
infants exposed to nonopioid substances in utero. One study assessed the risk of NAS among
heroin only, cocaine-only, and opioid and cocaine exposed infants and found the risk to be 14%,
6%, and 35%, respectively.[134] Another study assessed the risk NAS among infants born to
mothers with an opioid prescription filled and who used non-opioid substances during
pregnancy. Within this cohort, women who were also prescribed a psychotropic medication in
the third trimester (i.e., sedatives) delivered infants with a 1.3% risk of NAS diagnosis. In
addition, women who filled an opioid prescription and had a documented alcohol and/or
nonopioid use disorder had a 3.1% risk of delivering a NAS baby.[61] Another study that
assessed risk of NAS requiring pharmacological treatment among a cohort of NAS diagnosed
infants found the greatest risk to be among infants exposed to an opioid (i.e., methadone) and
another nonopioid substance (82.5%), followed by an opioid-only (80%), a single non-opioid
(68.3%), and a poly nonopioid (50%) in utero exposure.[62] Although no studies have
comparatively examined the risk of NAS among sedative- and stimulant-only exposures, 30% of
infants exposed to SSRIs during pregnancy were diagnosed with NAS and 4% of infants exposed
to methamphetamine required pharmacological treatment for NAS.[34, 135].
Although the literature differs with respect to study population and in utero drug class
exposure groups, the current study had a considerably higher risk of NAS among opioid exposed
neonates compared to other studies with mother’s who filled an opioid prescription during
pregnancy (i.e., 46% vs. 2.4% to 5.6%).[61, 133] This discrepancy is most likely due to
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differences in population characteristics. That is, the current study encompassed a more at-risk
population than women who filled an opioid prescription antenatally. The current study had a
comparable risk of NAS and risk of NAS requiring treatment among opioid-only exposed
neonates compared to study populations of mothers’ with an illicit and/or licit opioid
dependency.[132, 136, 137]
With respect to the literature, our study differentiates via exposure groups linked to the
highest risk of NAS requiring treatment. In the current study, the largest risk for pharmacological
treatment is among sedative-only exposure and it was followed by opioid-only and polysubstance with opioid exposures. The comparative study had methadone-only, methadone and
other, single non-methadone, and polysubstance non-methadone exposure groups with polysubstance and then single methadone exposures leading the pharmacological treatment risk.
Discrepancies could have resulted from different categorization of substance exposure groups.
According to our results, sedative-only exposures could have a lower occurrence, but result in
more severe NAS. Selective serotonin re-uptake inhibitors are common sedatives that are linked
to NAS diagnosis and pharmacological treatment of neonatal withdrawal and our study cohort
had a relatively high prevalence rate of 13% of mothers who used SSRIs during pregnancy. This
finding would be unearthed within the previous study, as sedative-only exposures would have
been categorized in a less granular exposure group of single non-methadone substances.
Clinical Implications
Variation existed among drug class-specific exposure groups and risk of NAS diagnosis
and NAS requiring pharmacological treatment. This variation indicates multiple substances can
lead to a NAS diagnosis, not just opioids, and diagnoses should be more specific to represent the
exposure that results in the withdrawal. Proper diagnosis of exposure is important to better treat
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patients and for research purposes of tracking substance use trends in this vulnerable motherinfant population.
In addition, we showed variation among the hierarchical ordering of exposures associated
with risk between NAS diagnosis and severity of NAS. Opioid exposure (single or multiple
substances) had the highest risk of NAS diagnoses, but was the second highest risk of NAS
requiring treatment; following sedative-only exposure. Further examination of sedative in utero
exposure resulting in more severe NAS, compared to other drug class-specific exposures is
indicated.
Clinically, this difference raises questions regarding hospital protocols identification and
treatment for newborns diagnosed with NAS. Regardless of the exposure, these infants are
largely being diagnosed and treated with the same protocol. The modified Finnegan scoring
system was created from opiate withdrawal signs and symptoms and it is the most common NAS
scoring tool used in American. In addition, 83% of US clinicians use an opiate (usually
methadone or morphine) as the first line of treatment for NAS.[138] Most cases of NAS are
linked to in utero opioid exposure. Therefore, in many cases the neonates withdrawing from nonopioid substances are then given opioids as treatment in the NICU. This could be problematic, as
iatrogenic NAS increased from 9% in 2003-2004 to 50% in 2010 to 2011. among infants treated
with morphine for postoperative, ventilated, or chronically ill conditions.[13] Therefore, future
research should focus on the effectiveness of current standardized diagnostic and treatment
opioid-based hospital protocols, in instances when there is a known non-opioid exposure status.
In addition, phenobarbital and clonidine are utilized as second-line therapy options for NAS
when first-line opioid based medications are ineffective.[139] Future research should explore the
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effectiveness of phenobarbital as a first-line treatment for sedative-exposed neonates with severe
NAS.
In addition to outlining absolute NAS and NAS requiring treatment risks among varying
in utero exposures, it is important to identify other significant maternal and obstetric factors that
increase the offspring’s likelihood of a NAS diagnosis. This information is helpful for clinicians
to better identify at-risk neonates that could have been undetected from typical substance
exposure screening methods (e.g., history of drug use, maternal intervening, and universal
maternal urine drug screen). With the current screening techniques, withdrawal signs and
symptoms could be mistaken as a ‘fussy’ baby and thus not be diagnosed and treated. In
addition, withdrawing infants could be sent home prematurely without a NAS diagnosis, as signs
and symptoms usually start 48-72 hours after birth.[140, 141]
Strength and Limitations
The current study benefited from utilization of biologic samples of the neonates to
identify in utero substance exposure. Meconium and/or umbilical cord tissue drug screens with
confirmatory testing following positive results are considered the most accurate and practical
non-invasive tests compared to other screening methods, for example maternal and neonatal
urine drug screens, hair sampling (results in higher false-positive results), and self-report from
interviewing.[46, 68] Although utilization of meconium and umbilical cord tissue drug screening
provided stronger evidence of exposure classification, there are limitations associated with this
type of exposure assessment. For example, a non-positive drug screen result does not exclude the
possibility that a mother used drugs during pregnancy because drug metabolites could be below
the cut-off values for positive tests and detection could depend on unique characteristics of drug
class-specific deposition in the meconium and/or UCT. In addition, certain substances associated
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with neonatal withdrawal are not screened in the meconium and UCT drug panels (i.e., alcohol,
nicotine, and caffeine) and meconium and UCT results did not perfectly mirror each other, as
meconium did not include buprenorphine while UCT. Detection of drugs depends on the extent
and stability of maternal drug use and the pattern and frequency of drug(s) used by the mother
cannot be determined by the aforementioned drug screens. Drugs administered during labor and
delivery could also be detected within meconium and UCT screening, though this is not a strong
limitation of the current study, as the cohort encompassed substance exposed neonates rather
than neonates with a positive biological drug screen.
The selected patient sample is a strength of the study as it targets a cohort of neonates
exposed to substances in utero. This criteria allows the study population to be more
generalizable, because it does not restrict patients to only those with a positive drug screen or
only mother-infants dyads with a NAS diagnosis. In addition, this generalizable population
allows researchers to appropriately study multiple drug class-specific exposures related to NAS,
which would not be accurately assessed via a population of women enrolled in opioid
maintenance therapy or women who filled an opioid prescription during pregnancy. This is
important, as the current study points out that nonopioid in utero substance exposure is also
linked to NAS. Although broad, the inclusion criteria could still have resulted in undetected
substance-using mothers. Therefore, neonates who met the criteria to be in the sampling frame
and who had a primary or secondary diagnosis of NAS (ICD-9-CM code 779.5) were also
included in the study (n=2).
Additionally, the study utilized a theoretical framework and captured homogeneity
among NAS-related hospital protocols. Relevant covariates were chosen via support of the
literature and utilization of a biopsychosocial theoretical framework. Although utilization of
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EMR data for a retrospective chart review was necessary, it is limiting as this data was collected
for clinical, not research, purposes. EMR data can include high missingness and issues related to
heterogeneity of information stored across patients’ records. Although the study was conducted
at one major birthing hospital (verse a multi-site study), it allowed for homogeneity among
trained staff on NAS-related maternal substance use and neonatal exposure screening
methodology and NAS scoring/diagnosis and treatment protocols.
Conclusions
Although substance use occurrence and documentation of drug class-specific substances
consumed during pregnancy is often unknown and/or difficult to detect, identification of
exposure type can impact clinical applications. Identification of drug class-specific exposure can
particularly impact NAS-related diagnoses, determined severity, and treatment protocols. The
current study supports numerous drug class-specific exposures that can be linked to NAS and
there are variations among these exposures with severity of NAS or NAS requiring treatment.
Future research should focus on the application and effectiveness of substance specific neonatal
exposure screening tools and tailored treatment protocols to most effectively target drug specific
withdrawal.
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Chapter 4
Assessment of in utero opiate and cocaine exposure detection: A comparison of meconium
analysis to alternative mother-infant biological and diagnostic indicators

Abstract
Objectives: Opioid and cocaine antenatal substance use can result in significant obstetric and
pediatric health implications. Accurate detection of in utero exposed neonates can improve
patient care and health outcomes. Therefore, we assessed the effectiveness of opiate and cocaine
antenatal exposure among mother-infant biological and diagnostic indicators collected at labor
and delivery hospital admission. Method: A retrospective medical chart review included 381
mother-infant dyads exposed to antenatal substances who had a meconium analysis conducted at
delivery between January 1st 2009 and March 3rd 2014. Alternative biological and diagnostic
indicators of maternal urine drug screens (UDS), maternal substance use ICD-9-CM codes, and
neonatal exposure diagnostic ICD-9-CM codes were compared against meconium results.
Performance of detection methods were analyzed via sensitivity and specificity analyses.
Results: Meconium identified the highest incidence of antenatal cocaine (5%) and opioid (41%)
in utero exposures. Among opiate exposures, maternal UDS had the highest sensitivity [.57,
95% CI: .45, .69] and specificity [.90, 95% CI: .83, .98] values. Cocaine had higher overall
accuracy scores, with the highest sensitivity value of maternal substance use diagnosis [.37, 95%
CI: .15, .59] and the highest specificity value of maternal UDS [.99, 95% CI: .98, 1.0].
Conclusion: Alternative detection measures collected at delivery were ineffective at identifying
in utero substance exposure, especially neonatal exposed ICD-9-CM codes. Findings indicate
many exposed neonates could be misdiagnosed or left untreated. Accurate antenatal exposure
identification at delivery is an important form of tertiary care that warrants development of
improved detection methods with standardized biological identification protocols.
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4.1 Introduction
Opioid and/or cocaine use during pregnancy can result in substantial negative healthrelated outcomes for the mother and newborn. Women who use substances during pregnancy are
at an increased medical and obstetric risk for poor nutrition, anemia, problems related to
infections, preterm labor, miscarriage, placental abruption, and postpartum hemorrhage.[142]
Newborns with intrauterine exposure to opioids and cocaine are at an increased risk of
prematurity, low birthweight, neurobehavioral symptoms, congenital malformations, neonatal
abstinence syndrome, longer hospital stays, and are more likely to be placed in foster care or
adoption.[11, 22, 143]
Despite the associated negative health implications, the occurrence of opioid and
substance use during pregnancy is alarmingly high. Antenatal licit and illicit opiate use has
increased nearly 5-fold in the United States between 2000 and 2009.[17] Although cocaine use
during pregnancy has declined since the mid-1980’s, it remains a significant public health threat,
as cocaine is still the second most common illicit drug of abuse among pregnant women.[144]
Ideally, substance use among women of childbearing age could be eliminated at the
primary prevention-level or at least substance using women could be identified early on in
pregnancy at the secondary prevention-level. Benefits of early identification of antenatal opioid
and/or cocaine use include educational parenting interventions, maternal drug treatment
enrollment (such as methadone or buprenorphine maintained therapy), and increased medical
observation during pregnancy.
Although the greatest harm reduction and cost-benefit approach would be prevention or
early detection, it is not always possible to detect maternal opioid and cocaine use during
pregnancy prior to labor and delivery (LD) hospital admission. Many substance using women
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have unplanned pregnancies and often lack adequate prenatal care.[145] In addition to logistic
barriers, antenatal substance use is associated with a plethora of maternal biopsychosocial risk
factors, such as poverty, psychiatric comorbidities, lack of social support, physical abuse,
sexually transmitted infections, and poor prenatal nutrition.[22, 143]
Many in utero substance exposed neonates go undetected, typically until LD hospital
admission where neonatal and maternal biological drug screens are conducted and/or neonatal
withdrawal symptoms are identified.[43, 44] Therefore, from a practical perspective it is
important to assess the effectiveness of drug detection screening measures collected at delivery,
where clinical data will be collected on every patient.
There is currently no optimal screening tool for identifying antenatal substance use,
though reviews outline pros and cons of various non-invasive screening methods utilized at LD
admission.[45, 115, 146] Open-ended and non-judgmental structured maternal interviewing can
be effective, especially for identifying cannabis use, but is susceptible to recall, interviewer, and
response bias.[46, 69, 115] Maternal urine drug screening (UDS) has several clinical indications
with minimal logistical barriers, though it is associated with a short window of detection and thus
it has a low sensitivity. Maternal hair analysis can produce high sensitivity diagnostics, but it is
associated with high false positive rates and collection issues, as long hair segments are needed
to widen the gestational detection window.[46, 50]. Neonatal urine analysis is considered a
traditional drug screening method, though it is limited by the faulty collection methods and a
short detection window.[45] Meconium, or the first stool that the neonate passes, is the specimen
of choice for in utero exposure detection because it exhibits high sensitivity, it is easy to collect,
and it has a large window of detection (i.e., it begins to form weeks 12th to 16th gestation). [45,
48, 147, 148] Although meconium serves as a reliable reservoir for drug and metabolite
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compounds, drawbacks include the necessity of confirmation tests to avoid false-positives, the
possibility of contaminated samples, and the comparatively slow turnaround time to obtain
confirmed test results. A newer method of umbilical cord tissue specimen mimics the strengths
of meconium drug screening, with additional pros of a faster turnaround of results and the
guarantee that every neonate will have a testable specimen.[45] The limitation to cord tissue
analysis is the lack of literature supporting interpretation of results and known disposition of
drugs in the specimen.[116]
While taking the strengths and limitations of drug screening methods into account,
increased medical observation of in utero substance exposure is necessary. Antenatal substance
exposure can result in NAS, which requires early identification and treatment post-delivery. NAS
is a constellation of central nervous system, metabolic vasomotor, respiratory, and
gastrointestinal disturbances a newborn experiences while withdrawing from in utero substance
exposure.[12] Neonatal abstinence syndrome primarily results from opioid in utero exposure
though other drugs, such as cocaine, have been linked to neonatal withdrawal.[22] Signs and
symptoms of neonatal withdrawal typically occur until 28 to 72 hours after birth and severe cases
require pharmacological treatment.[11] Screening and detection is crucial because undiagnosed
newborns could be released prematurely from the hospital, resulting in untreated withdrawal in a
less stable environment.
Considering the public health threat of substance use during pregnancy and the benefits
of accurate detection, alternative screening methods of maternal and neonatal diagnostic codes
and biological drug tests were assessed in an at-risk patient population. The purpose of the
current study was to assess the effectiveness of antenatal substance use detection among different
mother-infant dyad identification methods conducted at LD hospital admission.
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4.2 Methods
Sample
The current study aimed to compare sensitivity and specificity of various screening tests
to identify cocaine and opioid in utero exposed infants. A subpopulation was utilized from a
larger retrospective cohort of substance-using women who delivered a singleton live birth
(International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code
V27.0) at a major birthing center in north-central WV between January 1, 2009 and March 3,
2014. The original sample was restricted to mother-infants dyads of women aged 18 years or
older at delivery and newborns of at least 28 weeks gestational age. If a mother gave birth to
multiple babies during the study time frame, the first born that fit the sample criteria was
included in the study.
Inclusion criteria of the larger retrospective cohort consisted of women who had an active
drug use diagnosis at delivery (ICD-9-CM: 303.9x, 304.x, 305.x, 648.31, 648.32, 649.01,
649.02), a positive urine drug screen (for any drug) during the nine months prior to delivery
admission, were prescribed prescriptions of buprenorphine or methadone at delivery admission
prior to giving birth [61], and/or who delivered a baby diagnosed with NAS (ICD-9-CM: 779.5).
Mother-infant dyads were excluded if the mother did not deliver at the study hospital (n=5) or if
the neonate expired at the same delivery admission prior to collection of a meconium sample
(n=7). After the 12 exclusions, the original sample included 560 mother-infant dyads. Study
diagnostic indictors where derived from ICD-9-CM codes because ICD-10-CM codes were not
utilized during the study period. Please see the section 3.2 of this dissertation for additional
detailed information on the sample criteria and data collection methodology.
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Out of a possible 560 dyads, the current study utilized the subpopulation of 381 motherinfant dyads that had a neonatal meconium drug screen on record. Most (n=118) of the 179
infants that did not have a meconium test result were born after a universal neonatal drug screen
policy change that took place at the study hospital. Universal umbilical cord tissue drug screens
were initiated on all neonates born at the study hospital from March 1st 2013 onward. Prior to
universal cord tissue testing, meconium drug screens were conducted on all newborns suspected
of substance exposure. The study sample came from an at-risk patient population, therefore those
born prior to universal cord tissue testing without a meconium result on record (n= 61) most
likely resulted from unavailable and/or compromised specimen samples for confirmation testing
or, although less likely, they could have been missed via risk-based screening.
Determination of Cocaine and Opioid Use in Meconium Samples
As per hospital protocol, at least four grams of neonatal meconium specimens were
collected for routine clinical purposes and sent for analysis to Associated Regional and
University Pathologists (ARUP) laboratories in Salt Lake City, Utah. Specimens were stored and
transported at 20-25 degrees Celsius. Results were reported within one to four days of the lab
receiving the specimen. All valid meconium samples were screened by enzyme-linked
immunosorbent assay (ELISA) to identify the appropriate drug class. A limitation of meconium
drug screening is its ability to produce false positive results. Therefore, positive results were
followed by a confirmation test of a fully validated gas chromatography-mass spectrometry or
liquid chromatography-tandem mass spectrometry. Cocaine was screened as its own drug class.
For the purpose of this study, opioid exposure was indicated if the neonate had a positive
meconium result in the drug screen panel categories of opiates, methadone, and/or
propoxyphene. Please see Table 4.1 for the size of the sample required for testing, the screening
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cutoff (or concentration at which the test can detect a drug or metabolite), and the confirmation
cutoff for positive screens.
Maternal Urine Drug Screen
Maternal UDS were taken at the corresponding LD hospital admission. Tests were
ordered in the obstetrical setting by the maternal infant care center department as part of a
universal or risk-based screening. Universal maternal UDS was initiated on January 1, 2011 at
the study hospital. Prior to universal testing, women who had a documented, suspected, or
acknowledge maternal history of drug use (of which are included in the study’s cohort) or had
insufficient prenatal care were screened.
Enzyme Immunoassay methodology was utilized with a minimum collection volume of
one milliliter of urine at the study hospital’s laboratory, which was the performing laboratory.
Specimens were stored at ambient temperatures up to 24 hours and could be refrigerated up to 5
days. Confirmation of positive results were confirmed by mass spectrometry techniques.
For the purpose of the current study, only information on cocaine and opioid test results
were collected. Cocaine remained consistent on the UDS panel as ‘cocaine metabolite’ with the
decision cutoff level of 300 ng/mL. Therefore, all mothers with a documented UDS at LD were
included in the cocaine UDS-specific analysis (n= 327). During the study period the UDS panels
for opioid detection slightly evolved. Between May and June 2011, the opioid UDS panel
changed to include buprenorphine as a separate component with a cutoff level at 10 ng/mL. In
order to be properly compared to the meconium drug screen (without a buprenorphine panel), we
only compared the maternal opioid UDS panels to meconium (n=128).
Maternal UDS tests were determined to be positive for opioids if methadone, opiate,
and/or propoxyphene substances were detected at the 300 ng/mL level. Out of the 381 mother56

infant dyads, 199 mothers had the new UDS at LD admission (with buprenorphine), 128 had the
old UDS without buprenorphine, and 54 mothers were not given a UDS at delivery or their
specimen collection was not documented in the patients’ electronic medical records.
Maternal ICD-9-CM Diagnosis
Diagnostic criteria of maternal substance use for opioids and/or cocaine were collected at
LD hospital admission. Opioid use during pregnancy was captured if the electronic medical
records had an ICD-9-CM diagnostic code of 304.00, 304.01, 304.70, 304.71, 305.50, and/or
304.51. Cocaine use was captured if the electronic medical records had an ICD-9-CM diagnostic
code of 304.20, 304.21, 305.60, and/or 305.61. These diagnoses were defined as current use (i.e.,
not in remission) as a single or polysubstance exposure and ranged from dependence to
nondependent opioid and cocaine abuse.
Neonatal ICD-9-CM Diagnosis
Neonatal in utero substance exposure was measured via exposure diagnostic codes in the
neonates’ electronic medical record at first hospital admission (i.e., birth). Diagnosis of cocaine
and opioid exposure was determined from ICD-9-CM codes 760.72 and 760.75 (i.e., noxious
influences affecting the fetus and/or neonate).
Maternal and Neonatal Characteristics
In order to better describe the study patient population, maternal sociodemographic and
obstetric-related characteristics were captured. Easily accessible clinical parameters were
collected from patient’s electronic medical records via manual researcher and automatic hospital
decision support analyst extraction (see section 3.2).
Maternal characteristics captured at delivery included age, years of education completed,
marital status, Medicaid insurance type, residence, and history of substance use and/or mental
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health treatment. Marital status was operationalized as married, single, or other, with ‘other’
indicating mothers who were divorced, legally separated, or widowed. Residence was
categorized as rural, urban, and metropolitan and it was determined from patient’s county of
residence Rural-Urban 2013 Continuum Codes (RUCC).[76] Other covariates included selective
serotonin reuptake inhibitors (SSRIs) taken during pregnancy, maternal smoking status,
nulliparous and gravidity status, spontaneous abortions, number of prenatal care visits, and mode
of delivery (i.e., vaginal or cesarean). Nulliparous status and maternal gravidity did not include
the current birth (i.e., mother-infant dyad). Spontaneous abortions were defined as a nontherapeutic miscarriage before 20 weeks gestational age. Neonatal variables included gestational
age (weeks) and other growth parameters comprising of head circumference (centimeters), length
(centimeters), and weight (grams) measured at delivery.
Statistical Analysis
Descriptive statistics were utilized to better explain patient characteristics. Categorical
variables were represented as frequencies and percentages, normally distributed continuous
variables were displayed as mean and standard deviations, and skewed continuous variables were
presented as median and interquartile ranges. Patient characteristics were stratified by a positive
cocaine and/or opioid meconium test and deemed significant via Chi-square test and student’s ttest bivariate analysis.
Maternal UDS results, substance use diagnoses, and infant exposure diagnoses were
examined as alternative in utero substance exposure screening methods. These methods were
compared against meconium drug screens as the defined ‘gold standard’. Performance of the
screening tools were assessed by sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy measures (see Appendix F).[149]
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Sensitivity was defined as the number of true positives divided by the number of all
positive assessments (i.e., meconium tests). Specificity was the number of true negative
assessments divided by the number of all negative assessments. Positive predictive values (PPV)
equaled the number of true positives divided by the number of screening positives and negative
predictive values (NPV) was the number of true negatives divided by the number of screening
negatives. Accuracy was defined as the number of correct assessments divided by the number of
all assessments. True positive was defined as mother-infant dyads with a positive meconium
result and, for the same drug of interest, a positive alternative screen (i.e., maternal UDS,
maternal ICD-9-CM diagnostic use, and neonatal ICD-9-CM exposure). Alternatively, true
negative was defined as mother-infants dyads who had a negative meconium result and had a
negative alternative drug screen.
Binomial proportion estimates and asymptotic standard error (ASE) 95% confidence
intervals were reported. If two proportions had non-overlapping confidence intervals then they
were considered significantly different.[150] All analyses were conducted using SAS 9.4 and
significance was defined with a 2-tailed alpha of .05 (SAS Institute Inc., Cary, North Carolina).
Ethical approval of the current study was obtained from the Institutional Review Board of the
author’s academic institution.
4.3 Results
Characteristics of Patients
Of 381 mother-infant dyads with a corresponding meconium drug screen, 165 (43.3%)
were positive for cocaine or opioids (see Table 4.2). At delivery admission, mothers on average
were 26 years of age, had 12 years of completed education, a gravidity of 2.8, had 0 spontaneous
abortions, and had 9 prenatal care visits. Most women were single, had Medicaid insurance, lived
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in a metropolitan defined area, had a history of drug/mental health treatment, smoked cigarettes
at LD hospital admission, already delivered another child at time of current birth, and had a
vaginal mode of delivery for the birth under study. Although on the lower end of head width and
weight, newborn growth parameters were within typical ranges with a patient average gestational
age of 37.6 weeks, head width of 32.8 centimeters, length of 47.6 centimeters, and weight of
2,812.3 grams.[151]
Mothers who delivered a newborn with a positive meconium drug screen for cocaine or
opioids were significantly less likely to be first time moms and had more previous pregnancies
(gravidity). Newborns with a positive meconium drug screen were significantly younger
(gestational age), shorter (length), and weighed less at delivery compared to newborns without a
positive cocaine or opioid meconium test.
Screening Test Performance
In utero exposure of maternal cocaine and opioid use was observed via neonatal
meconium drug screens, maternal UDS, maternal diagnostic substance use codes, and neonatal
diagnostic exposure codes (see Table 4.3). Meconium analysis detected the highest incidence of
antenatal cocaine use (5%) and opioid use (40.9%).
Detection of in utero cocaine and opioid exposure was then compared between the three
screening tests and meconium drug screens as the gold standard. For opioid exposure, maternal
UDS had the highest sensitivity (56.7%) and specificity value (90.2%). Maternal UDS had the
highest PPV (86.4%) and maternal ICD-9-CM diagnostic code had the highest NPV (67.5%).
Maternal UDS had the highest accuracy value of 65.4%.
For the detection of cocaine, maternal ICD-9-CM diagnosis had the highest sensitivity
value (37%) and maternal UDS had the highest specificity value (99.7%). Maternal UDS also

60

had the highest PPV (85.7%), while maternal ICD-9-CM diagnosis had the highest NPV
(96.8%). Maternal UDS had the overall highest accuracy value of 96.3%.
4.4 Discussion
Screening Test Performance
The current study assessed the performance of alternative screening methods taken at
labor and delivery that detect whether a neonate was exposed to cocaine and/or opioids in utero.
Maternal UDS, maternal ICD-9-CM substance use diagnostic codes, and neonatal ICD-9-CM
exposure codes were compared to neonatal meconium drug screen results. Overall, there was
surprisingly low sensitivity and moderate to high specificity. This indicates if a neonate’s
meconium result for opioids or cocaine was negative then the alternative screening measure
would most likely be negative. In addition to specificity, negative predictive values (NPV) were
higher than positive predictive values (PPV). Therefore, among those who had a negative screen,
the probability of having a negative meconium test result was greater than the probability of
having a positive meconium result among those with a positive screen. Neonatal ICD-9-CM
exposure codes had the poorest performance, while maternal ICD-9-CM and UDS screens were
fairly similar across measures and drug-specific detection. A previous study that assessed highrisk maternal-infant dyads for in utero opiate and cocaine exposure similarly calculated higher
diagnostic values for specificity than sensitivity.[46] However, their sensitivity measures to
detect in utero substance exposure via structured maternal interview, maternal hair analysis, and
meconium drug analysis were considerably higher than those of the current study. This is likely
due to the different screening measures and techniques utilized. Women were screened
throughout pregnancy and the researchers compared one result with the result of the other two
methods, with both serving as the referent (i.e., if one of the two references were positive then
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the referent was positive). The current study is the first to compare meconium results to
alternative screening methods of maternal and/or neonatal ICD-9-CM codes for substance use
detection performance.
Screening performance varied between methods within drug class exposures. Within
opioid tests, maternal UDS had a significantly higher sensitivity score compared to neonatal
ICD-9-CM. Maternal UDS also had a significantly higher NPV score compared to neonatal ICD9-CM exposure codes and maternal substance use ICD-9-CM codes. Within cocaine tests, there
were no significant differences among accuracy tests between alternative screening methods.
Previous research found meconium analysis estimates of drug use during pregnancy were more
sensitive than maternal interviews for both opiate and cocaine use, though maternal UDS was not
assessed.[68] In addition, Ostre at al. found performance variation of in utero substance detection
between screening tools (i.e., maternal interview, maternal hair analysis, and meconium analysis)
among both cocaine and opiate exposure groups. Maternal hair analysis had the highest
sensitivity, with meconium being the second highest due to the high false-positive hair analysis
results.[46]
Comparing between opioid and cocaine in utero exposure, cocaine specificity tests were
significantly higher across all measures (maternal UDS, maternal ICD-9-CM, and neonatal ICD9-CM) compared to opioid positive results. Cocaine NPV scores had a significantly higher NPV
across all alternative screening measures compared to opioid tests. In addition, cocaine had a
higher accuracy score across all screening methods compared to opioid tests. Although cocaine
had low surprisingly low sensitivity values, overall alternative screening methods more
accurately detected cocaine in utero exposure compared to opioid exposure. Although Ostre et al.
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utilized different screening tools, the findings were in agreement that overall better detection
estimates were obtained with cocaine compared to opioids.[46]
Characteristics of Patients
The current study consists of substance exposed cohort, with 43% of the neonates
specifically positive for cocaine and opioids. The remaining 57% could be positive for drugs
other than cocaine and/or opioids or they could have had an exposure level that did not result in a
positive meconium drug screen. That is, their metabolites could be lower than the meconium
analysis cut-off values. With respect to the percent of in utero cocaine and opioid exposure
captured via the four screening tools, meconium detected the highest number of positive cocaine
and opioid results and second highest number of positive opioid results. Maternal UDS captured
the highest number of positive opioid results.
The majority of mothers in the study population had Medicaid insurance, smoked at LD
admission, and had a history of drug/mental health treatment, and on average completed 12 years
of education. Most women were single mothers and had at least one previous pregnancy. Women
attended an average of 9 prenatal care visits, which is lower than the recommended number of 15
visits for low to normal risk pregnancies. The frequency of prenatal care visits throughout
pregnancy should increase for high-risk patients, which is indicative of the study population
because of the substance-using pregnant cohort and high occurrence of cesarean deliveries (i.e.,
37%).[152, 153]
Although the study’s overall number of prenatal visits was low, the number of visits were
even lower among cocaine and/or opioid positive neonates (i.e., an average of 7.9). Substance
abuse treatment integrated into prenatal care visits is linked with improved maternal and neonatal
health.[154, 155] Therefore, this finding highlights a public health opportunity for treatment of
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maternal drug use during pregnancy. Specifically, women in the current study were at the
hospital on average 9 times at which early detection and intervention could take place.
Positive meconium cocaine and/or opioid results were significantly associated with
increased number of previous pregnancies and poor neonatal growth parameters (i.e., younger
gestational age, shorter length, and lower weight), compared to non-positive cocaine/opioid
results. This finding is in agreement with existing literature and highlights the importance of
tertiary care to prevent substance use during future pregnancies.[46, 68]
Clinical Implications
Study findings indicate that overall, the alternative screening methods had a moderate to
high specificity and low sensitivity estimates compared to meconium drug tests.[156] Thus, if a
neonate had a positive cocaine or opiate meconium result it is likely that the alternative screening
methods would not detect antenatal substance exposure. Accurate detection of in utero exposed
neonates is extremely important. This form of tertiary prevention (i.e., detection at delivery)
could result in increased length of medical observation during the newborn period, in order to
properly diagnose and treat the newborn for potential withdrawal. Additional benefits include
short and long term pediatric follow-up and, if necessary, breastfeeding restrictions. Indirect
benefits to identifying antenatal substance use at LD hospital admission include prevention of
postnatal infant exposure and decreased risk of antenatal drug use in future pregnancies.[115]
This finding is important since mothers in the present study who gave birth to a newborn with a
positive meconium result for cocaine or opiates were at an increased likelihood to have had
multiple pregnancies. If exposure at LD can be identified, treatments and interventions can not
only help the newborn infant but also future children of these mothers.
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Overall, despite the low sensitivity measures, alternative mother-infant biological and
diagnostic indicators performed better for cocaine than opioid in utero exposure. Recent trends of
substance use during pregnancy among women delivering in WV indicate that antenatal cocaine
use is decreasing, while opiate use has greatly increased (see chapter 2). Therefore, development
of more accurate opiate in utero substance exposure is warranted.
Neonatal ICD-9-CM diagnostic exposure codes performed poorly as detection for in
utero substance exposure, which indicated the study hospital is not properly utilizing this form of
screening. These codes should perfectly match the meconium results, as exposure diagnoses are
based off of mother opioid maintenance therapy enrollment, maternal self-report of use, or
maternal and/or neonatal biologic drug screens. This finding is of clinical importance because
utilization of these diagnostic codes are vital for research purposes, as they are widely used to
quantify the magnitude of this public health problem.[157] Poor data collection may result in
faulty research regarding epidemic detection, hypothesis generation, and evaluation of public
health intervention, policy and clinical practice. Furthermore, inaccurate data could lead to
inappropriate allocation of public health prevention and resources (e.g., fiscal or treatment
support).
Limitations
While interpreting the study findings, readers should be aware of potential limitations.
Neonatal meconium drug tests were utilized as the gold standard, to which other screening
methods were compared. Although meconium screening is favored for its long window of
detection and ease of collection, potential drawbacks include availability of uncompromised
specimens for every neonate and comparatively slow testing turnaround time.[69] With these
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pros and cons in mind, it is important to note that mass meconium drug screening in a clinical
setting is feasible and affordable, with costs approximating urine toxicology analysis.[46, 47]
Another limitation includes the sparse use of antenatal cocaine among the study
population. The few number of mother-infant dyads with meconium samples that tested positive
for cocaine likely resulted in the surprisingly low sensitivity and high specificity of cocainespecific results. Also, the current study was conducted at a single hospital and therefore
screening diagnostic generalizability of maternal substance use and neonatal exposure ICD-9CM codes could be lacking. However, comparisons between meconium and maternal urine drug
screens are likely generalizable because specimens were collected and sent to a national
reference laboratory for results. All positive results are confirmed in order to reduce falsepositives. Although this step is in place, it is important to consider the study findings with a
focus on medical detection, evaluation, and treatment, rather than in the context of criminal
prosecution.[146]
Conclusion
Alternative screening methods to detect in utero cocaine and opiate exposure at LD
hospital admission are specific but not sensitive in comparison to meconium test results.
Therefore, if a neonate has a negative meconium drug screen then they will likely have a
negative maternal UDS result, maternal substance use diagnosis, and/or neonatal exposure
diagnosis screening. In addition, a positive meconium test result will not likely be detected via
alternative screening methods at LD admission and therefore many exposed neonates would go
undetected. Neonatal ICD-9-CM exposure codes have particularly low sensitivity values,
indicating a lack of correct identification of exposed neonates via internationally recognized
ICD-9-CM diagnostic codes.
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Chapter 5
Discussion
5.1 Summary of Key Findings
This project utilized WV Health Care Authority Uniform Billing data between 2007 and
2013 to describe sub-state regional incidence rates and trends of neonatal antenatal exposure and
NAS diagnoses. Data from electronic medical records were also obtained to identify risk of NAS
and NAS requiring pharmacologic treatment among substance-using pregnant women who gave
birth at Ruby Memorial Hospital between 2009 and March 3rd 2014. A subpopulation of this
cohort was utilized to assess the effectiveness of maternal urine drug screens, maternal substance
use ICD-9-CM diagnostic codes, and neonatal ICD-9-CM exposure codes in detecting antenatal
substance use. The research concluded an overall increasing trend of NAS diagnoses in WV with
sub-state variations, which are substantially higher than national averages. The research also
established variation among drug class-specific in utero exposures and risk of NAS as well as
low sensitivity measures of alternative in utero exposure detection methods taken at labor and
delivery from a single hospital site.
West Virginia statewide estimates of NAS rates, trend over time, and documented
neonatal exposure was not previously unknown. The current study addressed this gap in the
literature and calculated that the statewide NAS incidence rate increased over 4-fold from 7.74 to
31.56 per 1,000 live births per year between 2007 and 2013. Study findings, compared to
available national estimates from 2009 to 2012, indicated that the WV rates increased more than
three times that of national annual averages.[16, 17]
Between 2007 and 2013, all but one of the six sub-state regions significantly increased
(region 3 did not significantly change). In 2013, the southeastern region of the state had the
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highest NAS rate with an IR of 48.76 per 1,000 live births. During the study period, neonatal
opioid exposure significantly increased, cocaine exposure signficantly decreased, and the rate of
hallucinogen exposure remained unchanged. Exposure rates were substantially lower than NAS
diagnostic rates. In addition, NAS infants were more likely to experience clinical conditions (i.e.,
respiratory diagnoses, feeding difficulty, and seizures), longer hospital length of stay, and were
more likely to be born to a mother insured by Medicaid.
A retrospective medical chart review of mother-infant dyads with antenatal substance
exposure was conducted at a major WV birthing hospital. This data was obtained in order to fill
the gap in the literature regarding risk of NAS among non-opioid in utero substance exposed
neonates. Drug class-specific exposure was defined via neonatal meconium drug screen results.
The substance exposed cohort had a 29% risk of being diagnosed with NAS and among infants
diagnosed 54% had NAS that required pharmacological treatment. Risk of NAS was highest
among opioid only and poly-substance with opioid exposures. This finding held consistent in the
regression model controlling for potential confounders. That is, neonates with opioid only or
poly-substance with opioid in utero exposures were significantly more likely to be diagnosed
with NAS compared to neonates with a non-positive meconium drug screen. Number of prenatal
care visits and maternal opioid maintenance therapy enrollment were independent risk factors for
delivering a newborn diagnosed with NAS. The drug class-specific exposure group rankings
varied between risk of NAS and NAS requiring pharmacological treatment. Among neonates
diagnosed with NAS, sedative only exposure and poly-substance with opioids had the highest
and second highest risk of NAS requiring treatment, respectively.
A subpopulation (n=381) of the substance exposed cohort from a retrospective medical
chart review was utilized to assess the effectiveness of in utero opioid and cocaine exposure
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diagnostic indicators collected at labor and delivery. This was the first study to evaluate the
effectiveness of in utero exposure detection among maternal and neonatal ICD-9-CM diagnostic
codes compared to a neonatal biological drug screen. Neonates with a positive drug screen
(n=165 or 43.3%) had a significantly younger gestational age, shorter birthlength, and lighter
birthweight compared to newborns without a positive screen. In addition, women who delivered
a newborn with a positive meconium screen were more likely to have a higher previous gravidity
and were less likely to be first time mothers.
Meconium analysis detected the highest incidence of antenatal cocaine and opiate in
utero exposure and was deemed the gold standard. Therefore, the alternative identification
methods of maternal urine drug screens (UDS), maternal ICD-9-CM substance use diagnoses,
and neonatal exposure ICD-9-CM diagnoses were compared to meconium results. Overall, the
alternative methods exhibited surprisingly low sensitivity and moderate to high specificity
measures. Neonatal ICD-9-CM exposure codes had the poorest overall performance, while
maternal UDS had the highest accuracy estimate. Despite low sensitivity measures, overall the
alternative detection methods more accurately identified cocaine in utero exposure compared to
opioid exposure.
Screening performance varied among alternative methods, within and between antenatal
opioid and cocaine exposures. Within opioid drug testing, Maternal UDS had significantly higher
sensitivity scores compared to neonatal ICD-9-CM and significantly higher NPV scores
compared to neonatal exposure and maternal substance use ICD-9-CM codes. There were no
significant differences among screening performance within cocaine drug testing. Screening
performance between antenatal exposure types showed cocaine specificity tests were
significantly higher across all alternative measures compared to opioid positive results. In
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addition, cocaine NPV scores were significantly higher across all alternative screening methods
compared to opioid detection.
5.2 Significance of the Study
The upward trend of NAS throughout WV is indicative of a rise in an at-risk pregnant
patient population in which NAS diagnoses are occurring at a much higher rate than what is
observed at the national level. NAS rates were the highest among patients who reside in the
southeastern sub-state region. Consequently, throughout the study period only one federally
funded opioid maintenance therapy facility that accepted pregnant women was located in this
region.[85, 100] There is a unique need for antenatal public health drug treatment and
preventative interventions in WV, specifcially targeted to the southeastern region of the state.
These findings suggest health policy officials should allocate resources to the southeast region in
order to improve access to substance use prevention efforts, treatment, and health care planning
during pregnancy.
In addition, the WV and sub-state NAS trends highlighted an increase in opiate and
decrease in cocaine in utero exposure via ICD-9-CM neonatal diagnostic codes. This finding is
clinically relevant because it could indicate a potential shift in the type of maternal antenatal
substance use. For clarification, this ‘shift’ would be described as a change in prevalence at the
population-level, as opposed to individual women switching from cocaine to opiate use during
pregnancy. Knowledge of population trends in type of drug use within a specific group can aid in
tailored public health prevention and outreach efforts.
Neonatal substance exposure rates were far lower than NAS rates. This finding indicates
underutilization of appropriate neonatal ICD-9-CM codes among WV birthing hospitals.
Therefore, utilization of this diagnostic codes for research and quality improvement purposes
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could greatly underestimate the targeted vulnerable population. Improved reporting of neonatal
exposure-specific diagnoses could advance effective research and surveillance efforts.
The second study indicated that multiple substances could lead to a NAS diagnosis and
that variations existed between drug class-specific exposure and heightened risk of NAS/NAS
requiring treatment. Although the majority of NAS cases were linked to an opioid antenatal
exposure, other substances can cross the placenta barrier and lead to an infant’s expression and
consequently a diagnosis of NAS.[11, 22] The study also indicated independent maternal risk
factors associated with delivering an infant diagnosed with NAS. This information could
improve health care professionals’ ability to identify high risk mothers, in order to indicate
earlier substance use screening and ensure extended mother-infant observation. The clinical
significance lies in the fact that withdrawal signs and symptoms can start 48 to 72 hours after
birth, therefore undiagnosed infants could be sent home prior to the onset of withdrawal.[11, 42]
Knowledge of risk of NAS and NAS requiring treatment among non-opioid in utero
exposed infants is important because, regardless of the exposure, NAS infants are largely being
diagnosed and treated via the same hospital protocols. The most common scoring tool utilized
for NAS diagnosis, treatment, dosage, and discharge guidelines was created specifically for
opiate withdrawal in term infants.[143] This can be problematic because although numerous
drug exposures can result in similar withdrawal signs and symptoms, there are likely some
differences that could result in a misdiagnosed case of NAS.[22] In addition, traditional
treatment guidelines recommend an opioid-based first line of treatment (i.e., morphine or
methadone).[11] Although opioid therapy for NAS management helps with bowl motility
inhibition and treatment of seizures, it might not be ideal for non-opioid induced NAS as
iatrogenic (or hospital-induced) NAS is a rising concern.[13, 158]
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The third study examined the effectiveness of in utero opiate and cocaine detection
among alternative mother-infant biological and diagnostic indicators taken at labor and delivery
hospital admission. Overall, alternative methods of maternal urine drug screen, maternal
substance use diagnosis, and neonatal exposure diagnosis performed poorly with low sensitivity
values compared to meconium analysis results. Therefore, solely utilizing these alternative
screening methods taken at labor and delivery would likely underestimate the number of exposed
newborns. This finding is of clinical importance because the use of ineffective detection methods
could result in unidentified newborns that would likely be left untreated and/or released from the
hospital prior to withdrawal symptom onset.[42] Identifying effective detection of antenatal
substance use at delivery is a form of tertiary prevention that could increase the length of medical
observation during the newborn period for diagnostics and treatment purposes. In addition,
accurate detection can help ensure pediatric follow-up, set potential breastfeeding restrictions,
prevent other postnatal exposures, and decrease risk of substance use during future pregnancies.
Neonatal ICD-9-CM diagnostic exposure codes had the lowest performance measures,
further indicating a lack of neonatal exposure code utilization at a major WV birthing hospital.
These diagnostic indicators are important to ensure exposure-specific tailored treatment
protocols for NAS. In addition, these codes are widely used amongst researchers to quantify the
occurrence and trend of NAS and to evaluate related public health interventions, policy, and
clinical practices.[157] Accurate use of neonatal exposure indicators is also important in order to
appropriately allocate public health prevention and treatment resources to combat NAS and
substance use during pregnancy.
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5.3 Strengths and limitations
There are inherent issues associated with WV Health Care Authority Uniform Billing
data. Reporting behavior could be revenue driven, thus if the costliness of a NAS diagnosis
changed over time then an influx in NAS cases could be a result from reporting behavioral
differences verses actual change in disease occurrence. In addition, population-based
surveillance is dependent on accurate statewide standardized coding practices. Potential hospital
billing practices and NAS diagnosis definitions could have been variable during the assessment
period and change over time. Increased medical awareness of the syndrome and more accurate
diagnoses from birthing hospitals located close to major medical centers could also potentially
inflate NAS rates. Alternatively, hospital billing data could led to underreported NAS and
neonatal substance exposure diagnoses if not all newborns were drug screened and/or if exposure
status was based on maternal self-report. Although inaccurate rates due to the above mentioned
reasons are possible, it is unlikely because NAS rates paralleled the opioid epidemic, drug
overdose death rates, and rise in painkiller prescribing rates.
West Virginia identifiable data were unavailable, therefore hospital discharges, rather
than individual patients, were the unit of observation. Although unlikely, due to the window of
withdrawal and natural course of the syndrome, NAS discharge data could result in duplication if
the same patient (i.e., a newborn) had multiple hospital admissions related to the diagnosis.
Duplication would likely underestimated NAS rates because it would increase the total
population (i.e., denominator) while the NAS cases (numerator) would remain constant as this
condition is likely to be diagnosed at the first hospital admission. These potential problems are
driven from the study design and data source utilized in the first study, thus solutions are limited
and constraints may simply be a limitation of the data. The chosen data source is beneficial
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because it is currently the best approach to obtaining retrospective statewide NAS rates of WV
residents as it is the only data source that currently captures all insurance types. Strictly using
Medicaid data could overestimate NAS rates because it would mostly capture the at-risk
population.
Potential limitations of the second and third study associated with the data source include
reliance of medical records, vulnerability to misinformation, and potential selection bias. There
are inherent issues relying on medical record data; such that, missing and/nor inaccurate
information might exist. Misinformation would most likely occur with identified maternal
characteristics and inaccurate exposure classification. If a patient is asked about their medical
history or substance use behavior before or during pregnancy data could be susceptible to recall
or reporting bias, especially if the mother feels judged or pressured to answer a certain way.[46]
Misclassification in neonatal in utero exposure classification could occur if they were exposed to
substances not included in the biological analysis drug panel and/or if the exposure was not
capture via the drug screen due to concentrations below a screening cutoff value. Selection bias
could occur by determining which patients met the study eligibility criteria. These potential
issues were combated with manual review of every maternal-infant electronic record for
accuracy and detailed data extraction. Extraction of maternal and neonatal characteristics were
chosen based off of supportive literature and the utilization of the biopsychosocial theoretical
framework. In addition, a broad inclusion criteria of substance use during pregnancy was utilized
that helped ensure a complete cohort of in utero exposed neonates. The study population was
therefore more generalizable to a substance using pregnant population, which allowed more
appropriate examination of multiple drug class antenatal exposures.

74

The second and third study utilized data collected at a single hospital. Although this
could be viewed as a limitation with respect to generalizability, it resulted as a study strength
because NAS protocols were established and well defined throughout the study period. This
standardization better enabled the researchers to assume homogeneity within the data. The
hospital staff had a standardized neonatal exposure screening methodology and was uniformly
trained on NAS scoring/diagnostic and treatment protocols.
There are pros and cons associated with utilizing umbilical cord tissue and meconium
specimen for drug screening (please see chapters 1 and 3 for more details). Although strengths
and weakness of the non-invasive biological drug tests can be argued, they are considered the
gold standard for neonatal in utero substance exposure detection.[45] The study hospital had a
protocol in place to universally screen newborns and mothers (via urine drug screens), which has
supported findings of feasible and affordable mass meconium and umbilical cord tissue drug
screening in clinical settings.[46, 47]
5.4 Future Research
West Virginia and sub-state NAS rates are sustainably higher than the national average
and are continuing to trend upwards. The relationship between sub-state NAS rates, the
proportion of available treatment options for pregnant women, and region-level maternal and
societal characteristics is not yet known. Future research should examine geographic availability
of opioid treatment programs for pregnant women and associated likelihood of delivering a
newborn with a NAS diagnosis, NAS requiring pharmacological treatment, and other neonatal
clinical outcomes. Potential barriers to treatment accessibility for this vulnerable population
should be identified, in order to improve patient care.
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The first study found an increase in opioid and decrease in cocaine neonatal exposure
diagnoses over time. Future research should target a potential population shift in maternal drug
use, as findings could indicate need based treatment options for substance using pregnant
women. In addition, future research should target the lack of neonatal exposure ICD-9-CM code
utilization. Policy changes related to mandating the assignment of neonatal exposure diagnostic
codes with every NAS diagnosis or adding NAS to WV’s list of reportable disease is worth
exploring. Future research should explore the potential benefits of implementing an interoperable
insurance/hospital system and/or statewide standardized surveillance system to track NAS
diagnoses and neonatal exposure codes.
Results for the second study indicate non-opioid antenatal exposures are linked to NAS.
This finding raises clinical concerns because currently practiced NAS diagnostic and treatment
protocols are based on opioid in utero exposures. Future research should focus on the
effectiveness of current standardized diagnostic and treatment opioid-based hospital protocols, in
instances when there is a known non-opioid exposure status. Creation of an exposure-tailored
diagnosis, assessment, and treatment protocol might be warranted.
The second study also found variation among the hierarchical ordering of exposures
associated with risk between NAS diagnosis and severity of NAS. Specifically, opioid exposure
(single or multiple substances) had the highest risk of NAS diagnoses, but sedative only in utero
exposure had the highest risk of NAS requiring treatment. Future research should further explore
this association. If sedative only in utero exposure leads to more severe NAS, compared to opiate
exposures, than reconsideration of the typical first-line treatment is warranted. Specifically,
future research should explore the effectiveness of phenobarbital or clonidine as a first-line
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treatment for sedative-exposed neonates, as opposed to the typical first-line opioid based
medication.
With respect to the third study, future research should target development of more
accurate in utero substance exposure screening methods. Despite the low sensitivity detection
methods for cocaine exposure, overall cocaine detection out performed opiate exposure
detection. This finding coupled with the increased use of opioids during pregnancy highlight the
importance of accurate detection methods, specifically for opiate in utero exposure. In addition,
the third study only assessed in utero opiate and cocaine exposure among mother-infant
biological and diagnostic indicators, taken at labor and delivery, compared to meconium
analysis. Therefore, future studies should assess alternative drug class exposures and screening
measures via a multi-site study.
In conclusion, study findings warrant future research that aim to identify the potential
harm of utilizing opioid-based hospital screening, diagnostic, and treatment protocols for
neonates with non-opioid in utero exposure. Tailored antenatal exposure-specific hospital
protocols might improve neonatal withdrawal symptoms and shorten hospital length of stay, as
well as prevent the possibility of iatrogenic NAS. The study also warrants a statewide
surveillance system to track NAS and neonatal exposure diagnoses, in order to estimate the
magnitude of the health problem, detect epidemics, and assess the effectiveness of health
practice or new policy measures. The study highlights a need for greater prevention and
treatment resources in WV, as well as accurate/feasible non-invasive exposure detection
methods. Early detection of substance use during pregnancy, coupled with integrated and
comprehensive multidisciplinary services, could improve treatment compliancy and maternal and
neonatal health outcomes. In addition, pregnancy can serve as an opportune window for public
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health intervention because women are motivated to get and stay clean. Health care providers
should focus on facilitating a caring relationship with their patients via non-judgmental
behaviors, in order to develop a strong support network, provide additional parenting skills,
educate parents on NAS, and prevent a future delivery of a NAS diagnosed infant.[159-161]
A multi-faceted approach should also be taken to address NAS from a primary prevention
standpoint. The public health goal is to deter opioid misuse during the preconception period.
Emerical evidence suggests patient-provider discussions regarding appropriate use of
contraceptive devices and the potential health risks of opiate use during pregnancy can help
prevent fetal substance expsoure and thus minimize the emerging public health threat of
NAS.[94, 162] Prescribing clinician’s can also use of the state prescription drug monitoring
program and required counsel about risk of opiate use during pregnancy to women of
childbearing age whom are prescribed narcotics.[94]
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Tables
Chapter 2 Table
Table 2.1. West Virginia Delivery Characteristics by Neonatal Abstinence Syndrome: HCA,UB
2007-2013
NAS
Characteristics
Total
Yes
No
P-value
Total sample
119605
1974 (1.65%)
117631 (98.35%)
Male
60923 (50.94%)
1053 (53.34%) 59870 (50.90%)
.0967 a
Neonatal substance exposure
Narcotics
<.0001 a
Yes
543 (0.45%)
98 (4.96%)
445 (0.38%)
No
119062 (99.55%) 1957 (99.14%) 117526 (99.91%)
Hallucinogenic agentsd
.0156 b
Yes
32 (0.03%)
--No
119573 (99.97%) 1957 (99.14%) 117526 (99.91%)
Cocaine
<.0001 b
Yes
122 (0.10%)
17 (0.86%)
105 (0.09%)
No
119483 (99.90%) 1957 (99.14%) 117526 (99.91%)
Presence of neonatal conditions
Respiratory diagnoses 10060 (8.41%)
400 (20.26%)
9660 (8.21%)
<.001 a
Feeding difficulty
872 (0.73%)
51 (2.58%)
821 (0.70%)
<.001 a
Seizure
158 (0.13%)
18 (0.91%)
140 (0.12%)
<.0001 b
Neonatal hospital length
of stay, Median (IQR)
2 (2, 3)
8 (4, 18)
2 (2, 3)
<.001 c
Insurance
<.001 a
Medicaid
65502 (54.77%)
1680 (85.11%) 63822 (54.26%)
d
Medicare
97 (0.08%)
--Other
45898 (38.37%)
277 (14.03%)
45621 (38.78%)
PEIA
8108 (6.78%)
16 (0.81%)
8092 (6.88%)
HCA,UB, Health Care Authority, Uniform Billing Database; NAS, Neonatal Abstinence
Syndrome; TCHG, Total hospital charge; IQR, Interquartile range; PEIA, Public Employees
Insurance Agency
a
Pearson Chi-square
b
Two-sided Fisher’s exact test
c
Wilcoxon Ranked Sum
d
Variable is not stratified via NAS diagnosis in order to comply with the HCA UB data user
agreement of not reporting data less than or equal to 10 counts per cell.
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Chapter 3 Tables
Table 3.1. Breakdown of neonatal biological drug screen results and drug-class exposure groups.*
Biological drug screen Total
Opioids Cannabis PolyOther
Non
only
only
substance
positive
with opioids
Umbilical cord tissuea
Opioids
34
23
0
11
0
Stimulants
4
0
0
2
2
Sedatives
15
0
0
3
12
Cannabinoids
15
0
7
8
1
Total
106
23
7
11
13
52
b
Meconium
Opioids
151
87
0
64
0
Stimulants
23
0
0
12
11
Sedatives
23
0
0
15
8
Cannabinoids
138
0
87
46
5
Total
370
110
75
94
6
166
*The umbilical cord tissue and meconium drug screen test results are not mutually exclusive.
The drug-class specific exposure categorization is mutually exclusive. There were no positive
PCP results and therefore this drug was not included in the groupings.
a
Umbilical cord tissue drug panel includes opioids: buprenorphine, codeine, dihyrocodenine,
fentanyl, hydrocodone, hydromorphone, meperidine, methadone, EDDP, acetylmorphine,
morphine, naloxone, naltrexone, oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol,
and desmehyltramadol, stimulants: amphetamine, benzoylecgonine, cocaethylene, cocaine,
MDMA, MDA, methamphetamine, and phentermine, sedatives: alprazolam, butalbital,
clonazepam, aminoclonazepam, flurazepam, desalkylflurazepam, ethylflurazepam, lorazepam,
midazolam, nitrazepam, nordiazepam, oxazepam, phenobarbital, secobarbital, temazepam,
triazolam, and zolpidem.
b
Meconium drug panel includes opioids: opiates, propoxyphene, and methadone and metabolite,
stimulants: cocaine and amphetamines, and sedatives: barbituates and benzodiazepines. Both
drug screens also include marijuana metabolite and phencyclidine (or PCP).
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Table 3.2. Risk of neonatal abstinence syndrome (NAS) and pharmacological treatment of
NAS among a cohort of substance-using mother-infant dyads.
NAS requiring
Risk of
NAS
treatment
NAS
cases/sample
cases/sample
requiring
size
Risk of NAS
size
treatment
Total cohort
139/476
29.2%
75/139
54.0%
Drug exposure
Opioids only
50/110
45.5%
27/50
54%
Cannabis only
12/94
12.8%
4/12
33.3%
Stimulants only
1/9
11.1%
0/1
0
Sedatives only
5/15
33.3%
4/5
80%
Poly-substance with
31/75
41.3%
21/31
67.7%
opioids
Poly-substance without 2/7
28.6%
1/2
50%
opioids
Non-positive
38/166
22.9%
18/38
47.4%
P-value*
<.0001
0.2702
*
Cochran-Mantel-Haenszel: General Association
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Table 3.3. Maternal and Neonatal Characteristics by neonatal abstinence syndrome diagnosis.
Characteristics
Overall
NAS
No NAS
p-value
Total
476
139 (29.2%)
337 (70.8%)
Year of delivery
0.51 a
2009
61 (12.8%)
11 (7.9%)
50 (14.8%)
2010
75 (15.8%)
20 (14.4%)
55 (16.3%)
2011
87 (18.3%)
36 (25.9%)
51 (15.1%)
2012
105 (22.1%)
33 (23.7%)
72 (21.4%)
2013
131 (27.5%)
34 (24.5%)
97 (28.8%)
2014
17 (3.6%)
5 (3.6%)
12 (3.6%)
Maternal age, mean (SD)
26.1 (5.1)
26.3 (4.4)
26.0 (5.3)
0.61 b
Years of maternal education,* 12 (11, 13)
12 (11, 13)
12 (11, 13)
0.11 c
median (IQR)
Marital status*
0.40 d
Married
106 (22.6%)
27 (19.7%)
79 (23.7%)
Single
304 (64.7%)
95 (69.3%)
209 (62.8%)
Other
60 (12.8%)
15 (11.0%)
45 (13.5%)
Medicaid insurance
375 (78.8%)
110 (79.1%)
265 (78.6%)
0.90 e
Residence
0.64 e
Metropolitan
256 (54.6%)
73 (52.9%)
183 (55.3%)
Non-metropolitan
213 (45.4%)
65 (47.1%)
148 (44.7%)
Family visited at hospital
374 (91.7%)
107 (89.9%)
267 (92.4%)
0.42 e
Maternal diagnosis of
100 (21.0%)
35 (25.2%)
65 (19.3%)
0.15 e
psychological condition
Physical abuse present
8 (1.7%)
3 (2.5%)
6 (1.8%)
1.00 f
Reported familial support
412 (97.4%)
115 (96.6%)
297 (97.7%)
0.52 f
History of chronic pain*
79 (17.3%)
30 (22.9%)
49 (15.0%)
0.04 e
History of drug/mental health 268 (57.0%)
104 (76.5%)
164 (49.1%)
<.0001 e
treatment*
Opioid maintenance therapy
209 (44.0%)
104 (74.8%)
105 (31.3%)
<.0001 e
Smoking packs per day*
0.5(0.2, 1.0)
0.5 (0.2, 1.0)
0.5 (0.2, 1.0)
0.11 c
SSRI use during pregnancy
60 (12.7%)
14 (10.1%)
46 (13.7%)
0.29 e
Nulliparous
177 (37.2%)
45 (32.4%)
132 (39.2%)
0.16 e
Gravidity, median (IQR)
2.0 (1, 4)
2 (1, 4)
3 (2, 4)
0.51 c
Spontaneous abortions,
0 (0, 1)
0 (0, 1)
0 (0, 1)
0.84 c
median (IQR)
Prenatal visits, mean (SD)
8.8 (5.7)
7.6 (5.0)
9.3 (6.0)
0.01 b
e
Delivery type
0.3362
Cesarean
176 (37.0%)
56 (40.3%)
120 (35.6%)
Vaginal
300 (63.0%)
83 (59. 7%)
217 (64.4%)
Maternal pre-pregnancy BMI, 22.6 (19.7, 27.5) 22.3 (19.7, 27.0) 22.7 (19.7, 27.5) 0.47 c
median (IQR)
Neonate sex
0.23 e
Male
240 (50.4%)
76 (54.7%)
164 (48.7%)
Female
236 (49.6%)
63 (45.3%)
173 (51.3%)
100

Gestational age, median (IQR) 38.1 (36.9, 39.2) 38.0 (37, 39)
38.3 (36.7, 39.3) 0.25 c
Head c (cm), median (IQR)
33.0 (31.5, 34)
33 (31, 34)
33 (32, 34)
0.71 c
Length (cm), mean (SD)
47.6 (3.8)
47.1 (4.1)
47.8 (3.7)
0.10 b
Weight (g), mean (SD)
2,816.7 (620.8)
2761.7 (630.8)
2839.4 (616.1)
0.22 b
Neonatal drug screen
specimen mode
Meconium
368 (77.3%)
106 (76.3%)
262 (77.7%)
0.72 e
Cord tissue
108 (22.7%)
33 (23.7%)
75 (22.3%)
Neonatal drug screen results**
<.0001 d
Opioids only
110 (23.1%)
50 (36.0%)
60 (17.8%)
Cannabis only
94 (19.8%)
12 (8.6%)
82 (24.3%)
Poly-substance with
75 (15.8%)
31 (22.3%)
44 (13.1%)
opioids
Other
31 (6.5%)
8 (5.8%)
23 (6.8%)
Non-positive
166 (34.9%)
38 (27.3%)
128 (38.0%)
NAS: Neonatal Abstinence Syndrome, STD: Standard deviation, IQR: Interquartile range, PPD:
Packs per day, SSRI: Selective serotonin re-uptake inhibitors, BMI: Body mass index, cm:
Centimeters, g: Grams
*Self-reported from patient
**Mutually exclusive in utero substance exposures via neonatal meconium or cord tissue drug
screen test results.
%: Column percent (calculations of sample and percent do not include missing values).
a
Cochran-Armitage Trend Test
b
T-Test
c
Wilcoxon Ranked Sum
d
Cochran-Mantel-Haenszel: General Association
e
Pearson chi-square
f
Two-sided Fisher’s exact test
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Table 3.4. Association between in utero substance exposure and neonatal abstinence
syndrome. (n=279)
Exposure
NAS
NAS
Crude
95% CI
aOR
95% CI
OR
Opioids only
2.81
(1.67, 4.73)
3.72
(1.54, 8.98)
Cannabis only
0.49
(0.24, 0.99)
0.83
(0.27, 2.62)
Poly-substance with opioids
2.37
(1.32, 4.26)
3.52
(1.13, 10.98)
Other
1.17
(0.49, 2.83)
1.44
(0.32, 6.46)
Non-positive (referent)
----NAS: Neonatal abstinence syndrome, OR: Odds ratio, CI: Confidence Interval, aOR:
Adjusted odds ratio, BMI: Body mass index, g: Grams
Adjusted for family visited during hospital admission, reported familial support, history of
chronic pain, history of mental health/substance use treatment, smoking packs per day,
number of prenatal care visits, maternal pre-pregnancy BMI, and opioid maintenance therapy.
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Chapter 4 Tables
Table 4.1. Meconium sample required and drug cutoff concentrations
Drug
Sample
Screen cutoff Confirmation cutoff
amount*
Cocaine
0.5 gram
30 ng/g
20 ng/g
Opioid
Opiates
0.125 gram
30 ng/g
20 ng/g
Methadone
0.125 gram
40 ng/g
20 ng/g
Propoxyphene
1 gram
75 ng/g
10 ng/g
*Minimum volume
ng/g: nanogram /gram
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Table 4.2. Maternal and Neonatal Characteristics by meconium results (n=381)
Characteristics
Overall
Meconium
Meconium
negative for
positive for
cocaine or
cocaine or
opioids
opioids
Total
381
216 (56.7%)
165 (43.3%)
Maternal age, mean (SD)
26.2 (5.1)
26.2 (5.1)
26.2 (5.2)
Years of maternal education,
12.1 (1.9)
12.2 (1.8)
11.9 (2.1)
mean (SD)
Marital status
Married
86 (23.6%)
54 (26.1%)
32 (20.4%)
Single
233 (64.0%)
131 (63.3%)
102 (65.0%)
Other*
45 (12.4%)
22 (10.6%)
23 (14.7%)
Medicaid insurance
Yes
288 (75.6%)
158 (73.2%)
130 (78.8%)
No
93 (24.4%)
58 (26.9%)
35 (21.2%)
Residence
Rural
14 (3.9%)
9 (4.3%)
5 (3.3%)
Urban
144 (39.7%)
83 (39.5%)
61 (39.9%)
Metropolitan
205 (56.5%)
118 (56.2%)
87 (56.9%)
History of drug/mental health
204 (55.9%)
107 (51.7%)
97 (61.4%)
treatment
SSRI use during pregnancy
47 (12.8%)
28 (13.3%)
19 (12.0%)
Smoking status
Current
279 (75.4%)
150 (71.4%)
129 (80.6%)
Former
53 (14.3%)
37 (17.6%)
16 (10.0%)
Never
15 (9.4%)
23 (11.0%)
15 (9.4%)
Nulliparous
135 (36.5%)
89 (42.4%)
46 (28.8%)
Gravidity, median (IQR)
2.8 (1, 4)
2 (1, 4)
2 (2, 4)
Spontaneous abortions, median
0 (0, 1)
0 (0, 1)
0 (0, 1)
(IQR)
Prenatal visits, mean (SD)
9.0 (6.0)
9.7 (6.2)
7.9 (5.2)
Mode of delivery
Cesarean
140 (36.8%)
80 (37.0%)
60 (36.4%)
Vaginal
241 (63. 3%)
136 (63.0%)
105 (63.6%)
Gestational age, mean (SD)
37.6 (2.4)
37.9 (2.3)
37.3 (2.5)
Head width (cm), mean (SD)
32.8 (2.4)
33.0 (2.2)
32.7 (2.8)
Length (cm), mean (SD)
47.6 (3.9)
48.1 (3.6)
46.9 (4.1)
Weight (g), mean (SD)
2812.3 (620.6) 2885.6 (606.6) 2716.0 (627.4)
SD: Standard deviation, SSRI: Selective serotonin reuptake inhibitor, IQR: Interquartile
range, cm: centimeters, g: grams
*’Other’ marital status incudes women who are divorced, legally separated, or widowed.
Percentages do not include missing values.
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Table 4.3. Estimates of in utero drug exposure in 381 mother-infant dyads by
neonatal meconium, maternal UDS, and diagnostic codes.
Meconium
Maternal urine Maternal
Neonatal
drug screen*
ICD-9-CM ICD-9-CM
Opioid positive
156 (40.9%) 44 (34.4%)
141 (37%) 90 (23.6%)
Cocaine positive
19 (5%)
7 (2.1%)
12 (3.1%)
9 (2.4%)
ICD-9-CM: International Classification of Disease, Ninth Revision, Clinical
Modification
*Values for cocaine-specific maternal urine drug screen were out of 327
mother-infant dyads, because 54 mothers did not have recorded urine drug
screen results in their electronic medical records in their labor and delivery
hospital admission. Opioid-specific maternal urine drug screens were out of
128, because 54 did not have a screen at labor and delivery, and 199 had the
new drug panel and thus were not used.
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Table 4.4. Detection of in utero opioid and cocaine exposure among maternal urine drug screen,
substance use diagnosis, and neonatal exposure diagnosis in comparison to meconium drug test.
Maternal UDS
Maternal ICD-9-CM
Neonatal ICD-9-CM
Opioid
Sensitivity (95% CI)
0.57 (0.45, 0.69)
0.50 (0.42, 0.58)
0.27 (0.20, 0.34)
Specificity (95% CI)
0.90 (0.83, 0.98)
0.72 (0.66, 0.78)
0.79 (0.73, 0.84)
PPV (95% CI)
0.86 (0.76, 0.97)
0.55 (0.47, 0.64)
0.47 (0.36, 0.57)
NPV (95% CI)
0.65 (0.55, 0.76)
0.68 (0.62, 0.73)
0.61 (0.55, 0.66)
Accuracy (95% CI)
0.65 (0.58, 0.72)
0.63 (0.58, 0.68)
0.58 (0.53, 0.62)
Cocaine
Sensitivity (95% CI)
0.333 (0.12, 0.55)
0.368 (0.15, 0.59)
0.27 (0.06, 0.46)
Specificity (95% CI)
0.997 (0.98, 1.00)
0.986 (0.97, 1.00)
0.99 (0.97, 1.00)
PPV (95% CI)
0.857 (0.42, 1.00)
0.583 (0.30, 0.86)
0.56 (0.23, 0.88)
NPV (95% CI)
0.963 (0.94, 0.98)
0.968 (0.95, 0.99)
0.96 (0.94, 0.98)
Accuracy (95% CI)
0.963 (0.94, 0.98)
0.955 (0.93, 0.98)
0.95 (0.93, 0.97)
UDS: Urine drug scree, ICD-9-CM: International Classification of Disease, Ninth Revision,
Clinical Modification, PPV: Positive predictive value, NPV: Negative predictive value, CI:
Confidence interval
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Figures
Chapter 2 Figures
Figure 2.1. SAMSHA West Virginia Region and Opioid Treatment Program Center Map
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Figure 2.2. West Virginia Regional and Hospital Neonatal Abstinence Syndrome Incidence Rate
per 1,000 Live Births
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Figure 2.3: Number of inpatient hospitalizations resulting from exposure to noxious substances,
West Virginia, 2007-2013
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Chapter 3 Figure
Figure 3.1. Biopsychosocial approach to understanding neonatal abstinence syndrome

110

Appendixes
A.
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B.
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C.
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Note: This is the data that was manually collected (i.e., not provided in full by the hospital
decision support analyst.)
118

D.

Note: I did not have to collect umbilical cord tissue data because it was provided by the
hospital decision support analyst.
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E.
Meconium Drug Cutoff Concentrations, ARUP Laboratory*
Drug
Screen cutoff
Confirmation
cutoff
Marijuana
30 ng/g
5 ng/g
Cocaine
30 ng/g
20 ng/g
Opiates
30 ng/g
2 ng/g
Phencyclidine
15 ng/g
10 ng/g
Amphetamines
30 ng/g
20 ng/g
Barbiturates
75 ng/g
50 ng/g
Methadone
40 ng/g
10 ng/g
Benzodiazepines
75 ng/g
20 ng/g
Propoxyphene
75 ng/g
10 ng/g
ARUP: Associated Regional and University Pathologists
laboratories in Salt Lake City, Utah, ng/g: nanogram /gram
*The methodology utilized is quantitative liquid
chromatography-tandem mass spectrometry
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Umbilical Cord Tissue Drug Cutoff Concentrations, ARUP Laboratory*
Drug class
Drug
Screen cutoff
Opioids
Buprenorphine
2 ng/g
Buprenorphine-G
8 ng/g
Codeine
6 ng/g
Dihydrocodeine
4 ng/g
Fentanyl
1 ng/g
Hydrocodone
6 ng/g
Hydromorphone
4 ng/g
Meperidine
2 ng/g
Methadone
10 ng/g
EDDP
10 ng/g
6-Acetylmorphine
4 ng/g
Morphine
4 ng/g
Naloxone
8 ng/g
Naltrexone
8 ng/g
Oxycodone
4 ng/g
Oxymorphone
4 ng/g
Propoxyphene
10 ng/g
Tapentadol
2 ng/g
Tramadol
2 ng/g
N-Desmethyltramadol
2 ng/g
O-Desmethyltramadol
2 ng/g
Stimulants
Amphetamine
8 ng/g
Benzoylecgonine
8 ng/g
M-Oh-Benzoylecgonine
8 ng/g
Cocaethylene
8 ng/g
Cocaine
8 ng/g
MDMA- Ecstasy
8 ng/g
MDA
8 ng/g
MDEA- EVE
8 ng/g
Methamphetamine
8 ng/g
Phentermine
8 ng/g
Sedatives-Hypnotics
Alprazolam
5 ng/g
Alpha-OH-Alprazolam
5 ng/g
Butalbital
40 ng/g
Clonazepam
5 ng/g
7-Aminoclonazepam
5 ng/g
Diazepam
5 ng/g
Flunitrazepam
5 ng/g
7-Aminoflunitrazepam
5 ng/g
Flurazepam
5 ng/g
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Desalkylflurazepam
2-OH-Ethylflurazepam
Lorazepam
Midazolam
Alpha-OH-Midazolam
Nitrazepam
Nordiazepam
Oxazepam
Phenobarbital
Secobarbital
Temazepam
Triazolam
Alpha-OH-Triazolam
Zolpidem

10 ng/g
10 ng/g
5 ng/g
5 ng/g
5 ng/g
5 ng/g
5 ng/g
5 ng/g
20 ng/g
40 ng/g
5 ng/g
5 ng/g
5 ng/g
10 ng/g

Phencyclidine-PCP

4 ng/g

Phencyclidine
Marijuana
Marijuana metabolite
150 pg/g
ARUP: Associated Regional and University Pathologists laboratories in
Salt Lake City, Utah, ng/g: nanogram /gram, pg/g: picogram/gram
*The methodology utilized is qualitative liquid chromatography-time of
flight mass spectrometry and enzyme-linked immunosorbent assay

122

F.
Definitions:
Sensitivity = TP/(TP + FN) = (Number of true positive assessment)/(Number of all positive
assessment) Specificity = TN/(TN + FP) = (Number of true negative assessment)/(Number of all
negative assessment) Accuracy = (TN + TP)/(TN+TP+FN+FP) = (Number of correct
assessments)/Number of all assessments)
Positive Predictive Value (PPV)= TP/(TP + FP)= Number of true positives/Number of test
positives
Negative Predictive Value (NPV)= TN/(TN + FN)= Number of true negatives/Number of test
negatives
Opioid Meconium & Maternal ICD-9-CM Diagnosed (opioid)
Meconium results
Mom diagnosed
Mom not diagnosed
Positive
78
78
Negative
63
162
Sensitivity: 0.50, ASE confidence limits (0.419, 0.581)
Specificity: 0.72, ASE confidence limits (0.6613, 0.7787)
PPV: 0.5532, ASE confidence limits (0.4711, 0.6353)
NPV: 0.6750, ASE confidence limits (0.6157, 0.7343)
Accuracy: 0.6299, ASE confidence limits (0.5814, 0.6784)
Opioid Meconium & Maternal UDS (opioid)
Meconium results
+ UDS
- UDS
Positive
38
29
Negative
6
55
Sensitivity: 0.5672, ASE confidence limits (0.4485, 0.6858)
Specificity: 0.9016, ASE confidence limits (0.8269, 0.9764)
PPV: 0.8636, ASE confidence limits (0.7622, 0.9650)
NPV: 0.6548, ASE confidence limits (0.5531, 0.7564)
Accuracy: 0.6538, ASE confidence limits (0.5847, 0.7227)
Opioid Meconium & Neonatal exposure diagnosis (opioid)
Meconium results
Neonatal diagnosed
Neonatal not diagnosed
Positive
42
114
Negative
48
177
Sensitivity: 0.2692, ASE confidence limits (0.1996, 0.3388)
Specificity: 0.7867, ASE confidence limits (0.7331, 0.8402)
PPV: 0.4667, ASE confidence limits (0.3636, 0.5697)
NPV: 0.6082, ASE confidence limits (0.5522, 0.6643)
Accuracy: 0.5748, ASE confidence limits (0.5252, 0.6244)

Total
156
225

Total
67
61

Total
156
225
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Cocaine Meconium & Maternal ICD-9-CM Diagnosed (cocaine)
Meconium results
Mom diagnosed
Mom not diagnosed
Positive
7
12
Negative
5
357
Sensitivity: 0.3684, ASE confidence limits (0.1515, 0.5853)
Specificity: 0.9862, ASE confidence limits (0.9742, 9982)
PPV: 0.5833, ASE confidence limits (0.3044, 0.8623)
NPV: 0.9675, ASE confidence limits (0.9494, 0.9856)
Accuracy: 0.9554, ASE confidence limits (0.9346, 0.9761)
Cocaine Meconium & Maternal UDS (cocaine)
Meconium results
+ UDS
- UDS
Positive
38
29
Negative
6
55
Sensitivity: 0.5672, ASE confidence limits (0.4485, 0.6858)
Specificity: 0.9016, ASE confidence limits (0.8269, 0.9764)
PPV: 0.8636, ASE confidence limits (0.7622, 0.9650)
NPV: 0.6548, ASE confidence limits (0.5531, 0.7564)
Accuracy: 0.6538, ASE confidence limits (0.5847, 0.7227)
Cocaine Meconium & Neonatal exposure diagnosis (cocaine)
Meconium results
Neonatal diagnosed
Neonatal not diagnosed
Positive
5
14
Negative
4
358
Sensitivity: 0.2692, ASE confidence limits (0.0652, 0.4612)
Specificity: 0.9890, ASE confidence limits (0.9720, 0.9970)
PPV: 0.5556, ASE confidence limits (0.2309, 0.8802)
NPV: 0.9624, ASE confidence limits (0.9430, 0.9817)
Accuracy: 0.9528, ASE confidence limits (0.9315, 0.9741)

Total
19
362

Total
67
61

Total
19
362
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